<?xml version="1.0" encoding="UTF-8"?><!-- Normalized for easier text mining. --><xocs:doc xmlns:xocs="http://www.elsevier.com/xml/xocs/dtd" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.elsevier.com/xml/ja/dtd" xmlns:ja="http://www.elsevier.com/xml/ja/dtd" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:tb="http://www.elsevier.com/xml/common/table/dtd" xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd" xmlns:ce="http://www.elsevier.com/xml/common/dtd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:cals="http://www.elsevier.com/xml/common/cals/dtd" xsi:schemaLocation="http://www.elsevier.com/xml/xocs/dtd http://schema.elsevier.com/dtds/document/fulltext/xcr/xocs-article.xsd"><xocs:meta><xocs:content-family>serial</xocs:content-family><xocs:content-type>JL</xocs:content-type><xocs:cid>280959</xocs:cid><xocs:srctitle>Cell Reports</xocs:srctitle><xocs:normalized-srctitle>CELLREPORTS</xocs:normalized-srctitle><xocs:orig-load-date>2012-10-11</xocs:orig-load-date><xocs:ew-transaction-id>2013-02-14T16:18:56</xocs:ew-transaction-id><xocs:eid>1-s2.0-S2211124712002884</xocs:eid><xocs:pii-formatted>S2211-1247(12)00288-4</xocs:pii-formatted><xocs:pii-unformatted>S2211124712002884</xocs:pii-unformatted><xocs:doi>10.1016/j.celrep.2012.09.007</xocs:doi><xocs:item-stage>S300</xocs:item-stage><xocs:item-version-number>S300.1</xocs:item-version-number><xocs:item-weight>FULL-TEXT</xocs:item-weight><xocs:hub-eid>1-s2.0-S2211124712X00111</xocs:hub-eid><xocs:timestamp>2014-02-03T15:49:16.823947-05:00</xocs:timestamp><xocs:issns><xocs:issn-primary-formatted>2211-1247</xocs:issn-primary-formatted><xocs:issn-primary-unformatted>22111247</xocs:issn-primary-unformatted></xocs:issns><xocs:crossmark>false</xocs:crossmark><xocs:vol-first>2</xocs:vol-first><xocs:iss-first>4</xocs:iss-first><xocs:vol-iss-suppl-text>Volume 2, Issue 4</xocs:vol-iss-suppl-text><xocs:sort-order>11</xocs:sort-order><xocs:first-fp>789</xocs:first-fp><xocs:last-lp>798</xocs:last-lp><xocs:pages><xocs:first-page>789</xocs:first-page><xocs:last-page>798</xocs:last-page></xocs:pages><xocs:cover-date-orig><xocs:start-date>20121025</xocs:start-date></xocs:cover-date-orig><xocs:cover-date-text>25 October 2012</xocs:cover-date-text><xocs:cover-date-start>2012-10-25</xocs:cover-date-start><xocs:cover-date-year>2012</xocs:cover-date-year><xocs:hub-sec><xocs:hub-sec-title>Reports</xocs:hub-sec-title></xocs:hub-sec><xocs:document-type>article</xocs:document-type><xocs:document-subtype>sco</xocs:document-subtype><xocs:copyright-line>Copyright © 2012 The Authors. Published by Elsevier Inc. All rights reserved.</xocs:copyright-line><xocs:normalized-article-title>INDUCEDPLURIPOTENTSTEMCELLMODELSPROGRANULINDEFICIENTFRONTOTEMPORALDEMENTIAUNCOVERSPECIFICREVERSIBLENEURONALDEFECTS</xocs:normalized-article-title><xocs:normalized-first-auth-surname>ALMEIDA</xocs:normalized-first-auth-surname><xocs:normalized-first-auth-initial>S</xocs:normalized-first-auth-initial><xocs:item-toc><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-section-title>Introduction</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-section-title>Results</xocs:item-toc-section-title><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-section-title>Generation and Characterization of FTD-Patient-Specific iPSCs</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-section-title>Differentiation of FTD-Patient-Specific iPSCs into Neurons</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-section-title>A Human Neuronal Model of PGRN Haploinsufficiency</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-section-title>PGRN S116X Neurons Are More Sensitive to Cellular Stress Induced by Inhibitors of the Phosphatidylinositol 3-Kinase/Akt and MEK/Mitogen-Activated Protein Kinase Signaling Pathways</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-section-title>The Cellular and Molecular Defects of PGRN S116X Neurons Can be Rescued by PGRN Expression</xocs:item-toc-section-title></xocs:item-toc-entry></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-section-title>Discussion</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-section-title>Experimental Procedures</xocs:item-toc-section-title><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-section-title>Isolation of Primary Human Skin Fibroblasts and Generation of iPSCs</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-section-title>qRT-PCR, Immunocytochemistry, Differentiation and Characterization of iPSCs, and Electrophysiology</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-section-title>PGRN Measurements</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-section-title>Stress-Induced Toxicity Assay</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-section-title>PGRN Rescue Experiments</xocs:item-toc-section-title></xocs:item-toc-entry></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:acknowledgment"><xocs:item-toc-section-title>Acknowledgments</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:appendices"><xocs:item-toc-section-title>Accession Numbers</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:appendices"><xocs:item-toc-section-title>Supplemental Information</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:bibliography"><xocs:item-toc-section-title>References</xocs:item-toc-section-title></xocs:item-toc-entry></xocs:item-toc><xocs:references><xocs:ref-info refid="bib1"><xocs:ref-normalized-surname>AHMED</xocs:ref-normalized-surname><xocs:ref-pub-year>2010</xocs:ref-pub-year><xocs:ref-first-fp>311</xocs:ref-first-fp><xocs:ref-last-lp>324</xocs:ref-last-lp><xocs:ref-normalized-initial>Z</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="bib2"><xocs:ref-normalized-surname>BAKER</xocs:ref-normalized-surname><xocs:ref-pub-year>2006</xocs:ref-pub-year><xocs:ref-first-fp>916</xocs:ref-first-fp><xocs:ref-last-lp>919</xocs:ref-last-lp><xocs:ref-normalized-initial>M</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="bib3"><xocs:ref-normalized-surname>BOXER</xocs:ref-normalized-surname><xocs:ref-pub-year>2005</xocs:ref-pub-year><xocs:ref-first-fp>S3</xocs:ref-first-fp><xocs:ref-last-lp>S6</xocs:ref-last-lp><xocs:ref-normalized-initial>A</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="bib4"><xocs:ref-normalized-surname>CHENPLOTKIN</xocs:ref-normalized-surname><xocs:ref-pub-year>2008</xocs:ref-pub-year><xocs:ref-first-fp>1349</xocs:ref-first-fp><xocs:ref-last-lp>1362</xocs:ref-last-lp><xocs:ref-normalized-initial>A</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="bib5"><xocs:ref-normalized-surname>CHENPLOTKIN</xocs:ref-normalized-surname><xocs:ref-pub-year>2010</xocs:ref-pub-year><xocs:ref-first-fp>111</xocs:ref-first-fp><xocs:ref-last-lp>122</xocs:ref-last-lp><xocs:ref-normalized-initial>A</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="bib6"><xocs:ref-normalized-surname>COLLA</xocs:ref-normalized-surname><xocs:ref-pub-year>2012</xocs:ref-pub-year><xocs:ref-first-fp>3306</xocs:ref-first-fp><xocs:ref-last-lp>3320</xocs:ref-last-lp><xocs:ref-normalized-initial>E</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="bib7"><xocs:ref-normalized-surname>COPPOLA</xocs:ref-normalized-surname><xocs:ref-pub-year>2008</xocs:ref-pub-year><xocs:ref-first-fp>92</xocs:ref-first-fp><xocs:ref-last-lp>96</xocs:ref-last-lp><xocs:ref-normalized-initial>G</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="bib8"><xocs:ref-normalized-surname>CRUTS</xocs:ref-normalized-surname><xocs:ref-pub-year>2006</xocs:ref-pub-year><xocs:ref-first-fp>920</xocs:ref-first-fp><xocs:ref-last-lp>924</xocs:ref-last-lp><xocs:ref-normalized-initial>M</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="bib9"><xocs:ref-normalized-surname>DEJESUSHERNANDEZ</xocs:ref-normalized-surname><xocs:ref-pub-year>2011</xocs:ref-pub-year><xocs:ref-first-fp>245</xocs:ref-first-fp><xocs:ref-last-lp>256</xocs:ref-last-lp><xocs:ref-normalized-initial>M</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="bib10"><xocs:ref-normalized-surname>DELALOY</xocs:ref-normalized-surname><xocs:ref-pub-year>2010</xocs:ref-pub-year><xocs:ref-first-fp>323</xocs:ref-first-fp><xocs:ref-last-lp>335</xocs:ref-last-lp><xocs:ref-normalized-initial>C</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="bib11"><xocs:ref-normalized-surname>DIMOS</xocs:ref-normalized-surname><xocs:ref-pub-year>2008</xocs:ref-pub-year><xocs:ref-first-fp>1218</xocs:ref-first-fp><xocs:ref-last-lp>1221</xocs:ref-last-lp><xocs:ref-normalized-initial>J</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="bib12"><xocs:ref-normalized-surname>EBERT</xocs:ref-normalized-surname><xocs:ref-pub-year>2009</xocs:ref-pub-year><xocs:ref-first-fp>277</xocs:ref-first-fp><xocs:ref-last-lp>280</xocs:ref-last-lp><xocs:ref-normalized-initial>A</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="bib13"><xocs:ref-normalized-surname>FENTON</xocs:ref-normalized-surname><xocs:ref-pub-year>2011</xocs:ref-pub-year><xocs:ref-first-fp>47</xocs:ref-first-fp><xocs:ref-last-lp>59</xocs:ref-last-lp><xocs:ref-normalized-initial>T</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="bib14"><xocs:ref-normalized-surname>FREBERG</xocs:ref-normalized-surname><xocs:ref-pub-year>2007</xocs:ref-pub-year><xocs:ref-first-fp>1543</xocs:ref-first-fp><xocs:ref-last-lp>1553</xocs:ref-last-lp><xocs:ref-normalized-initial>C</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="bib15"><xocs:ref-normalized-surname>FINCH</xocs:ref-normalized-surname><xocs:ref-pub-year>2009</xocs:ref-pub-year><xocs:ref-first-fp>583</xocs:ref-first-fp><xocs:ref-last-lp>591</xocs:ref-last-lp><xocs:ref-normalized-initial>N</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="bib16"><xocs:ref-normalized-surname>GHOSHAL</xocs:ref-normalized-surname><xocs:ref-pub-year>2012</xocs:ref-pub-year><xocs:ref-first-fp>395</xocs:ref-first-fp><xocs:ref-last-lp>408</xocs:ref-last-lp><xocs:ref-normalized-initial>N</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="bib17"><xocs:ref-normalized-surname>HE</xocs:ref-normalized-surname><xocs:ref-pub-year>2003</xocs:ref-pub-year><xocs:ref-first-fp>600</xocs:ref-first-fp><xocs:ref-last-lp>612</xocs:ref-last-lp><xocs:ref-normalized-initial>Z</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="bib18"><xocs:ref-normalized-surname>HOOZEMANS</xocs:ref-normalized-surname><xocs:ref-pub-year>2009</xocs:ref-pub-year><xocs:ref-first-fp>1241</xocs:ref-first-fp><xocs:ref-last-lp>1251</xocs:ref-last-lp><xocs:ref-normalized-initial>J</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="bib19"><xocs:ref-normalized-surname>ISRAEL</xocs:ref-normalized-surname><xocs:ref-pub-year>2012</xocs:ref-pub-year><xocs:ref-first-fp>216</xocs:ref-first-fp><xocs:ref-last-lp>220</xocs:ref-last-lp><xocs:ref-normalized-initial>M</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="bib20"><xocs:ref-normalized-surname>MATUS</xocs:ref-normalized-surname><xocs:ref-pub-year>2011</xocs:ref-pub-year><xocs:ref-first-fp>239</xocs:ref-first-fp><xocs:ref-last-lp>252</xocs:ref-last-lp><xocs:ref-normalized-initial>S</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="bib21"><xocs:ref-normalized-surname>NAPOLI</xocs:ref-normalized-surname><xocs:ref-pub-year>2009</xocs:ref-pub-year><xocs:ref-first-fp>1660</xocs:ref-first-fp><xocs:ref-last-lp>1671</xocs:ref-last-lp><xocs:ref-normalized-initial>I</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="bib22"><xocs:ref-normalized-surname>NEUMANN</xocs:ref-normalized-surname><xocs:ref-pub-year>2006</xocs:ref-pub-year><xocs:ref-first-fp>130</xocs:ref-first-fp><xocs:ref-last-lp>133</xocs:ref-last-lp><xocs:ref-normalized-initial>M</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="bib23"><xocs:ref-normalized-surname>NGUYEN</xocs:ref-normalized-surname><xocs:ref-pub-year>2011</xocs:ref-pub-year><xocs:ref-first-fp>267</xocs:ref-first-fp><xocs:ref-last-lp>280</xocs:ref-last-lp><xocs:ref-normalized-initial>H</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="bib24"><xocs:ref-normalized-surname>NIJHOLT</xocs:ref-normalized-surname><xocs:ref-pub-year>2012</xocs:ref-pub-year><xocs:ref-first-fp>693</xocs:ref-first-fp><xocs:ref-last-lp>702</xocs:ref-last-lp><xocs:ref-normalized-initial>D</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="bib25"><xocs:ref-normalized-surname>PETKAU</xocs:ref-normalized-surname><xocs:ref-pub-year>2012</xocs:ref-pub-year><xocs:ref-first-fp>711</xocs:ref-first-fp><xocs:ref-last-lp>722</xocs:ref-last-lp><xocs:ref-normalized-initial>T</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="bib26"><xocs:ref-normalized-surname>ROSEN</xocs:ref-normalized-surname><xocs:ref-pub-year>2011</xocs:ref-pub-year><xocs:ref-first-fp>1030</xocs:ref-first-fp><xocs:ref-last-lp>1042</xocs:ref-last-lp><xocs:ref-normalized-initial>E</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="bib27"><xocs:ref-normalized-surname>RYAN</xocs:ref-normalized-surname><xocs:ref-pub-year>2009</xocs:ref-pub-year><xocs:ref-first-fp>130</xocs:ref-first-fp><xocs:ref-normalized-initial>C</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="bib28"><xocs:ref-normalized-surname>RENTON</xocs:ref-normalized-surname><xocs:ref-pub-year>2011</xocs:ref-pub-year><xocs:ref-first-fp>257</xocs:ref-first-fp><xocs:ref-last-lp>268</xocs:ref-last-lp><xocs:ref-normalized-initial>A</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="bib29"><xocs:ref-normalized-surname>SCHON</xocs:ref-normalized-surname><xocs:ref-pub-year>2011</xocs:ref-pub-year><xocs:ref-first-fp>1033</xocs:ref-first-fp><xocs:ref-last-lp>1053</xocs:ref-last-lp><xocs:ref-normalized-initial>E</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="bib30"><xocs:ref-normalized-surname>SKIBINSKI</xocs:ref-normalized-surname><xocs:ref-pub-year>2005</xocs:ref-pub-year><xocs:ref-first-fp>806</xocs:ref-first-fp><xocs:ref-last-lp>808</xocs:ref-last-lp><xocs:ref-normalized-initial>G</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="bib31"><xocs:ref-normalized-surname>SOLDNER</xocs:ref-normalized-surname><xocs:ref-pub-year>2009</xocs:ref-pub-year><xocs:ref-first-fp>964</xocs:ref-first-fp><xocs:ref-last-lp>977</xocs:ref-last-lp><xocs:ref-normalized-initial>F</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="bib32"><xocs:ref-normalized-surname>TAPIA</xocs:ref-normalized-surname><xocs:ref-pub-year>2011</xocs:ref-pub-year><xocs:ref-first-fp>11126</xocs:ref-first-fp><xocs:ref-last-lp>11132</xocs:ref-last-lp><xocs:ref-normalized-initial>L</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="bib33"><xocs:ref-normalized-surname>TAKAHASHI</xocs:ref-normalized-surname><xocs:ref-pub-year>2007</xocs:ref-pub-year><xocs:ref-first-fp>861</xocs:ref-first-fp><xocs:ref-last-lp>872</xocs:ref-last-lp><xocs:ref-normalized-initial>K</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="bib34"><xocs:ref-normalized-surname>VANDAMME</xocs:ref-normalized-surname><xocs:ref-pub-year>2008</xocs:ref-pub-year><xocs:ref-first-fp>37</xocs:ref-first-fp><xocs:ref-last-lp>41</xocs:ref-last-lp><xocs:ref-normalized-initial>P</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="bib35"><xocs:ref-normalized-surname>WATTS</xocs:ref-normalized-surname><xocs:ref-pub-year>2004</xocs:ref-pub-year><xocs:ref-first-fp>377</xocs:ref-first-fp><xocs:ref-last-lp>381</xocs:ref-last-lp><xocs:ref-normalized-initial>G</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="bib36"><xocs:ref-normalized-surname>XU</xocs:ref-normalized-surname><xocs:ref-pub-year>2011</xocs:ref-pub-year><xocs:ref-normalized-initial>J</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="bib37"><xocs:ref-normalized-surname>YAMANAKA</xocs:ref-normalized-surname><xocs:ref-pub-year>2007</xocs:ref-pub-year><xocs:ref-first-fp>39</xocs:ref-first-fp><xocs:ref-last-lp>49</xocs:ref-last-lp><xocs:ref-normalized-initial>S</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="bib38"><xocs:ref-normalized-surname>YIN</xocs:ref-normalized-surname><xocs:ref-pub-year>2010</xocs:ref-pub-year><xocs:ref-first-fp>117</xocs:ref-first-fp><xocs:ref-last-lp>128</xocs:ref-last-lp><xocs:ref-normalized-initial>F</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="bib39"><xocs:ref-normalized-surname>ZANOCCOMARANI</xocs:ref-normalized-surname><xocs:ref-pub-year>1999</xocs:ref-pub-year><xocs:ref-first-fp>5331</xocs:ref-first-fp><xocs:ref-last-lp>5340</xocs:ref-last-lp><xocs:ref-normalized-initial>T</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="bib40"><xocs:ref-normalized-surname>ZHANG</xocs:ref-normalized-surname><xocs:ref-pub-year>2007</xocs:ref-pub-year><xocs:ref-first-fp>10530</xocs:ref-first-fp><xocs:ref-last-lp>10534</xocs:ref-last-lp><xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial></xocs:ref-info></xocs:references><xocs:attachment-metadata-doc><xocs:attachment-set-type>item</xocs:attachment-set-type><xocs:pii-formatted>S2211-1247(12)00288-4</xocs:pii-formatted><xocs:pii-unformatted>S2211124712002884</xocs:pii-unformatted><xocs:eid>1-s2.0-S2211124712002884</xocs:eid><xocs:doi>10.1016/j.celrep.2012.09.007</xocs:doi><xocs:cid>280959</xocs:cid><xocs:timestamp>2013-02-14T13:18:48.818087-05:00</xocs:timestamp><xocs:path>/280959/1-s2.0-S2211124712X00111/1-s2.0-S2211124712002884/</xocs:path><xocs:cover-date-start>2012-10-25</xocs:cover-date-start><xocs:attachments><xocs:web-pdf><xocs:attachment-eid>1-s2.0-S2211124712002884-main.pdf</xocs:attachment-eid><xocs:filename>main.pdf</xocs:filename><xocs:extension>pdf</xocs:extension><xocs:pdf-optimized>true</xocs:pdf-optimized><xocs:filesize>2379045</xocs:filesize><xocs:web-pdf-purpose>MAIN</xocs:web-pdf-purpose><xocs:web-pdf-page-count>10</xocs:web-pdf-page-count><xocs:web-pdf-images><xocs:web-pdf-image><xocs:attachment-eid>1-s2.0-S2211124712002884-main_1.png</xocs:attachment-eid><xocs:filename>main_1.png</xocs:filename><xocs:extension>png</xocs:extension><xocs:filesize>132113</xocs:filesize><xocs:pixel-height>849</xocs:pixel-height><xocs:pixel-width>656</xocs:pixel-width><xocs:attachment-type>IMAGE-WEB-PDF</xocs:attachment-type><xocs:pdf-page-num>1</xocs:pdf-page-num></xocs:web-pdf-image></xocs:web-pdf-images></xocs:web-pdf><xocs:attachment><xocs:attachment-eid>1-s2.0-S2211124712002884-gr4.jpg</xocs:attachment-eid><xocs:file-basename>gr4</xocs:file-basename><xocs:filename>gr4.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>185116</xocs:filesize><xocs:pixel-height>808</xocs:pixel-height><xocs:pixel-width>745</xocs:pixel-width><xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S2211124712002884-gr3.jpg</xocs:attachment-eid><xocs:file-basename>gr3</xocs:file-basename><xocs:filename>gr3.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>75885</xocs:filesize><xocs:pixel-height>402</xocs:pixel-height><xocs:pixel-width>656</xocs:pixel-width><xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S2211124712002884-gr2.jpg</xocs:attachment-eid><xocs:file-basename>gr2</xocs:file-basename><xocs:filename>gr2.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>119578</xocs:filesize><xocs:pixel-height>625</xocs:pixel-height><xocs:pixel-width>656</xocs:pixel-width><xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S2211124712002884-gr1.jpg</xocs:attachment-eid><xocs:file-basename>gr1</xocs:file-basename><xocs:filename>gr1.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>253251</xocs:filesize><xocs:pixel-height>852</xocs:pixel-height><xocs:pixel-width>668</xocs:pixel-width><xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S2211124712002884-fx1.jpg</xocs:attachment-eid><xocs:file-basename>fx1</xocs:file-basename><xocs:abstract-attachment>true</xocs:abstract-attachment><xocs:filename>fx1.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>40603</xocs:filesize><xocs:pixel-height>300</xocs:pixel-height><xocs:pixel-width>375</xocs:pixel-width><xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S2211124712002884-figs4.jpg</xocs:attachment-eid><xocs:file-basename>figs4</xocs:file-basename><xocs:filename>figs4.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>129766</xocs:filesize><xocs:pixel-height>770</xocs:pixel-height><xocs:pixel-width>589</xocs:pixel-width><xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S2211124712002884-figs3.jpg</xocs:attachment-eid><xocs:file-basename>figs3</xocs:file-basename><xocs:filename>figs3.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>77372</xocs:filesize><xocs:pixel-height>388</xocs:pixel-height><xocs:pixel-width>769</xocs:pixel-width><xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S2211124712002884-figs2.jpg</xocs:attachment-eid><xocs:file-basename>figs2</xocs:file-basename><xocs:filename>figs2.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>87083</xocs:filesize><xocs:pixel-height>610</xocs:pixel-height><xocs:pixel-width>656</xocs:pixel-width><xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S2211124712002884-figs1.jpg</xocs:attachment-eid><xocs:file-basename>figs1</xocs:file-basename><xocs:filename>figs1.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>131435</xocs:filesize><xocs:pixel-height>479</xocs:pixel-height><xocs:pixel-width>656</xocs:pixel-width><xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S2211124712002884-gr4.sml</xocs:attachment-eid><xocs:file-basename>gr4</xocs:file-basename><xocs:filename>gr4.sml</xocs:filename><xocs:extension>sml</xocs:extension><xocs:filesize>9299</xocs:filesize><xocs:pixel-height>164</xocs:pixel-height><xocs:pixel-width>151</xocs:pixel-width><xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S2211124712002884-gr3.sml</xocs:attachment-eid><xocs:file-basename>gr3</xocs:file-basename><xocs:filename>gr3.sml</xocs:filename><xocs:extension>sml</xocs:extension><xocs:filesize>6259</xocs:filesize><xocs:pixel-height>134</xocs:pixel-height><xocs:pixel-width>219</xocs:pixel-width><xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S2211124712002884-gr2.sml</xocs:attachment-eid><xocs:file-basename>gr2</xocs:file-basename><xocs:filename>gr2.sml</xocs:filename><xocs:extension>sml</xocs:extension><xocs:filesize>9676</xocs:filesize><xocs:pixel-height>164</xocs:pixel-height><xocs:pixel-width>172</xocs:pixel-width><xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S2211124712002884-gr1.sml</xocs:attachment-eid><xocs:file-basename>gr1</xocs:file-basename><xocs:filename>gr1.sml</xocs:filename><xocs:extension>sml</xocs:extension><xocs:filesize>10736</xocs:filesize><xocs:pixel-height>163</xocs:pixel-height><xocs:pixel-width>128</xocs:pixel-width><xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S2211124712002884-fx1.sml</xocs:attachment-eid><xocs:file-basename>fx1</xocs:file-basename><xocs:abstract-attachment>true</xocs:abstract-attachment><xocs:filename>fx1.sml</xocs:filename><xocs:extension>sml</xocs:extension><xocs:filesize>13531</xocs:filesize><xocs:pixel-height>164</xocs:pixel-height><xocs:pixel-width>205</xocs:pixel-width><xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S2211124712002884-figs4.sml</xocs:attachment-eid><xocs:file-basename>figs4</xocs:file-basename><xocs:filename>figs4.sml</xocs:filename><xocs:extension>sml</xocs:extension><xocs:filesize>7116</xocs:filesize><xocs:pixel-height>163</xocs:pixel-height><xocs:pixel-width>125</xocs:pixel-width><xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S2211124712002884-figs3.sml</xocs:attachment-eid><xocs:file-basename>figs3</xocs:file-basename><xocs:filename>figs3.sml</xocs:filename><xocs:extension>sml</xocs:extension><xocs:filesize>7325</xocs:filesize><xocs:pixel-height>110</xocs:pixel-height><xocs:pixel-width>219</xocs:pixel-width><xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S2211124712002884-figs2.sml</xocs:attachment-eid><xocs:file-basename>figs2</xocs:file-basename><xocs:filename>figs2.sml</xocs:filename><xocs:extension>sml</xocs:extension><xocs:filesize>7800</xocs:filesize><xocs:pixel-height>164</xocs:pixel-height><xocs:pixel-width>176</xocs:pixel-width><xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S2211124712002884-figs1.sml</xocs:attachment-eid><xocs:file-basename>figs1</xocs:file-basename><xocs:filename>figs1.sml</xocs:filename><xocs:extension>sml</xocs:extension><xocs:filesize>15087</xocs:filesize><xocs:pixel-height>160</xocs:pixel-height><xocs:pixel-width>219</xocs:pixel-width><xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S2211124712002884-mmc2.pdf</xocs:attachment-eid><xocs:file-basename>mmc2</xocs:file-basename><xocs:filename>mmc2.pdf</xocs:filename><xocs:extension>pdf</xocs:extension><xocs:pdf-optimized>true</xocs:pdf-optimized><xocs:filesize>3922266</xocs:filesize><xocs:attachment-type>APPLICATION</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S2211124712002884-mmc1.pdf</xocs:attachment-eid><xocs:file-basename>mmc1</xocs:file-basename><xocs:filename>mmc1.pdf</xocs:filename><xocs:extension>pdf</xocs:extension><xocs:pdf-optimized>true</xocs:pdf-optimized><xocs:filesize>11069</xocs:filesize><xocs:attachment-type>APPLICATION</xocs:attachment-type></xocs:attachment></xocs:attachments></xocs:attachment-metadata-doc><xocs:refkeys><xocs:refkey3>ALMEIDAX2012X789</xocs:refkey3><xocs:refkey4lp>ALMEIDAX2012X789X798</xocs:refkey4lp><xocs:refkey4ai>ALMEIDAX2012X789XS</xocs:refkey4ai><xocs:refkey5>ALMEIDAX2012X789X798XS</xocs:refkey5></xocs:refkeys><xocs:open-access><xocs:oa-access-effective-date>2013-07-20T14:37:35Z</xocs:oa-access-effective-date><xocs:oa-access-inherited-from winid="http://vtw.elsevier.com/content/oaw/22111247_UNBOUNDED_Author">OA-Window</xocs:oa-access-inherited-from><xocs:oa-article-status is-open-access="1" is-open-archive="0">Full</xocs:oa-article-status><xocs:oa-sponsor><xocs:oa-sponsor-type>Author</xocs:oa-sponsor-type></xocs:oa-sponsor><xocs:oa-user-license>http://creativecommons.org/licenses/by/3.0/</xocs:oa-user-license></xocs:open-access></xocs:meta><xocs:serial-item><article docsubtype="sco" version="5.1" xml:lang="en"><item-info><jid>CELREP</jid><aid>172</aid><ce:pii>S2211-1247(12)00288-4</ce:pii><ce:doi>10.1016/j.celrep.2012.09.007</ce:doi><ce:copyright type="other" year="2012">The Authors</ce:copyright></item-info><ce:floats><ce:figure id="fig1"><ce:label>Figure 1</ce:label><ce:caption><ce:simple-para id="fspara0010" view="all">Generation and Characterization of FTD Patient-Specific iPSCs</ce:simple-para><ce:simple-para id="fspara0015" view="all">(A-C) Total and endogenous (Endo) levels of the reprogramming factors in control, sporadic, and PGRN S116X iPSC lines relative to the values in H9, as assessed by qRT-PCR. Values are mean ± SEM.</ce:simple-para><ce:simple-para id="fspara0020" view="all">(D) Genomic DNA sequencing of the heterozygous PGRN S116X mutation g.4627C &gt; A (p.S116X: nonsense mutation) in PGRN S116X iPSCs.</ce:simple-para><ce:simple-para id="fspara0025" view="all">(E) Methylation status of the <ce:italic>OCT4</ce:italic> promoter for control iPSC line 20, sporadic iPSC line 9, and PGRN S116X iPSC line 26. ○, unmethylated CpG dinucleotides; ●, methylated CpG dinucleotides.</ce:simple-para><ce:simple-para id="fspara0030" view="all">(F) Immunofluorescence analysis of pluripotency markers in control iPSC line 20, sporadic iPSC line 9, and PGRN S116X iPSC line 26, and their respective normal karyotypes. Cell nuclei were counterstained with DAPI (blue). Scale bar, 50 μm.</ce:simple-para><ce:simple-para id="fspara0035" view="all">(G) In vitro (EB formation) and in vivo (teratoma formation) differentiation of control iPSC line 20, sporadic iPSC line 9, and PGRN S116X iPSC line 26 into cells of all three germ layers. For in vitro studies, cells were immunostained with α-fetoprotein (AFP, endoderm), desmin (mesoderm), βIII-tubulin (ectoderm), and DAPI (nuclei). Hematoxylin/eosin staining of teratoma sections showed neuron/rosette structures (ectoderm), smooth muscle (mesoderm), and ducts (endoderm). Scale bar, 50 μm.</ce:simple-para><ce:simple-para id="fspara0040" view="all">See also <ce:cross-ref refid="figs1">Figure S1</ce:cross-ref>.</ce:simple-para></ce:caption><ce:link locator="gr1"/></ce:figure><ce:figure id="fig2"><ce:label>Figure 2</ce:label><ce:caption><ce:simple-para id="fspara0045" view="all">Differentiation and Characterization of Human Postmitotic Neurons Derived from FTD and Control iPSCs</ce:simple-para><ce:simple-para id="fspara0050" view="all">(A-E) Phase-contrast images of the cells at different stages of neuronal differentiation. Scale bar, 100 μm.</ce:simple-para><ce:simple-para id="fspara0055" view="all">(F) Representative images of 2-week-old cells stained with MAP2. Nuclear staining is shown in blue.</ce:simple-para><ce:simple-para id="fspara0060" view="all">(G and K) Cells positive for MAP2 and GFAP as a percentage of all cells in 2-week-old cultures.</ce:simple-para><ce:simple-para id="fspara0065" view="all">(H-J) Cells positive for VGLUT1, GABA, and TH (glutamatergic, GABAergic, and dopaminergic markers, respectively) as a percentage of MAP<ce:sup loc="post">+</ce:sup> cells. On average, 200 cells were analyzed per experiment in (G)-(K) (n = 3 independent cultures). Values are mean ± SEM.</ce:simple-para><ce:simple-para id="fspara0070" view="all">(L) Electrophysiological properties of control neurons and PGRN S116X neurons. Representative action potentials responding to step depolarization by current injection from 0 pA to 400 pA (100 pA step) that could be blocked by tetrodotoxin (n = 24 for each line).</ce:simple-para><ce:simple-para id="fspara0075" view="all">(M) Sample traces of mEPSCs from control (blue) and PGRN S116X (black) neurons. All neurons (n = 10 for each line) displayed synaptic responses and were abolished by the AMPA receptor antagonist NBQX.</ce:simple-para><ce:simple-para id="fspara0080" view="all">(N) Averaged mEPSC traces from control (blue) and PGRN S116X (black) neurons.</ce:simple-para><ce:simple-para id="fspara0085" view="all">See also <ce:cross-ref refid="figs2">Figure S2</ce:cross-ref>.</ce:simple-para></ce:caption><ce:link locator="gr2"/></ce:figure><ce:figure id="fig3"><ce:label>Figure 3</ce:label><ce:caption><ce:simple-para id="fspara0090" view="all">FTD Patient-Specific Neuronal Model of PGRN Haploinsufficiency</ce:simple-para><ce:simple-para id="fspara0095" view="all">(A) <ce:italic>GRN</ce:italic> mRNA expression levels in fibroblasts.</ce:simple-para><ce:simple-para id="fspara0100" view="all">(B and D) <ce:italic>GRN</ce:italic> mRNA expression levels in iPSC lines derived from control, sporadic, and PGRN S116X subjects (B) and neurons differentiated from iPSCs (D). The values from control (fibroblasts) or control line 20 were set to one (n = 3-4 independent cultures).</ce:simple-para><ce:simple-para id="fspara0105" view="all">(C and E) Amount of PGRN secreted into the medium over 24 hr by iPSCs (C) and iPSC-derived neurons (E). Values of control line 20 were set to 100% (n = 3-4 independent cultures).</ce:simple-para><ce:simple-para id="fspara0110" view="all">(F) Intracellular PGRN levels in iPSC-derived neurons after medium collection. Values of control line 20 were set to 100% (n = 3-4 independent cultures).</ce:simple-para><ce:simple-para id="fspara0115" view="all">Values in (A)-(F) are mean ± SEM. <ce:sup loc="pre">∗∗∗</ce:sup>p &lt; 0.001; patient cells were compared with control cells. See also <ce:cross-ref refid="figs3">Figure S3</ce:cross-ref>.</ce:simple-para></ce:caption><ce:link locator="gr3"/></ce:figure><ce:figure id="fig4"><ce:label>Figure 4</ce:label><ce:caption><ce:simple-para id="fspara0120" view="all">Novel Cellular and Molecular Defects of PGRN S116X Neurons Can Be Rescued by PGRN Expression</ce:simple-para><ce:simple-para id="fspara0125" view="all">(A-C) Effects of stress inducers on human neurons. Values are expressed as a percentage of the cells exposed to DMSO (control; n = 3-4 independent cultures).</ce:simple-para><ce:simple-para id="fspara0130" view="all">(D) Caspase-3-like activity after exposure to 10 nM staurosporine, 0.5 μM tunicamycin, or DMSO for 24 hr.</ce:simple-para><ce:simple-para id="fspara0135" view="all">(E and F) Measurement of cell viability (E) and caspase-3 activation (F) after rescue with PGRN expression (n = 5-6 independent cultures).</ce:simple-para><ce:simple-para id="fspara0140" view="all">(G) Heat map depicting fold changes of gene expression in two to three neuron cultures differentiated from each one of the four iPSC lines from the sporadic FTD patient (blue) or the PGRN S116X patient (fucsia) compared with control neurons.</ce:simple-para><ce:simple-para id="fspara0145" view="all">(H) Gene expression changes on the array for <ce:italic>GRN</ce:italic> and <ce:italic>RPS6KB2</ce:italic>. The log fold change is relative to control neurons.</ce:simple-para><ce:simple-para id="fspara0150" view="all">(I and J) PGRN expression restores S6K2 protein levels in PGRN S116X neurons.</ce:simple-para><ce:simple-para id="fspara0155" view="all">(I) Representative western blotting image for S6K2 (control line 17 and PGRN S116X line 1).</ce:simple-para><ce:simple-para id="fspara0160" view="all">(J) Quantification of S6K2 relative to GAPDH for three experiments performed on lines 17 and 20 (control), and lines 1 and 26 (PGRN S116X).</ce:simple-para><ce:simple-para id="fspara0165" view="all">In all panels, values are mean ± SEM. <ce:sup loc="pre">∗</ce:sup>p &lt; 0.05, <ce:sup loc="pre">∗∗</ce:sup>p &lt; 0.01, <ce:sup loc="pre">∗∗∗</ce:sup>p &lt; 0.001. See also <ce:cross-ref refid="figs4">Figure S4</ce:cross-ref>.</ce:simple-para></ce:caption><ce:link locator="gr4"/></ce:figure><ce:figure id="figs1"><ce:label>Figure S1</ce:label><ce:caption><ce:simple-para view="extended" id="fspara0170">Expression of Pluripotency Markers, In Vitro Spontaneous Differentiation of iPSCs into all Germ Layers, and Karyotyping Analysis, Related to <ce:cross-ref refid="fig1">Figure 1</ce:cross-ref></ce:simple-para><ce:simple-para view="extended" id="fspara0175">(A) qRT-PCR analysis showing mRNA levels relative to <ce:italic>GAPDH</ce:italic>. The values from ESC H9 were set to one. Values are mean ± SEM.</ce:simple-para><ce:simple-para view="extended" id="fspara0180">(B) Immunofluorescence staining of control (lines 16 and 17), sporadic (lines 12 and 23), and PGRN S116X (lines 1 and 14) iPSCs for TRA-1-81, NANOG, TRA-1-60, OCT4, SSEA4, and DAPI (blue). Scale bar: 50 μm.</ce:simple-para><ce:simple-para view="extended" id="fspara0185">(C) Control lines 16 and 17, sporadic lines 12 and 23, and PGRN S116X lines 1 and 14 were immunostained for AFP (endoderm), desmin (mesoderm), and βIII-tubulin (ectoderm), and counterstained with DAPI (nuclei). All lines showed a normal karyotype. Scale bar: 50 μm.</ce:simple-para></ce:caption><ce:link locator="figs1"/></ce:figure><ce:figure id="figs2"><ce:label>Figure S2</ce:label><ce:caption><ce:simple-para view="extended" id="fspara0190">Characterization of Human Postmitotic Neurons Derived from FTD and Control iPSCs, Related to <ce:cross-ref refid="fig2">Figure 2</ce:cross-ref></ce:simple-para><ce:simple-para view="extended" id="fspara0195">(A-D) Quantification of <ce:italic>VGLUT1</ce:italic>, <ce:italic>GABA</ce:italic>, <ce:italic>TH</ce:italic>, and <ce:italic>PSD95</ce:italic> mRNA expression levels. Each individual is represented by two lines. No significant differences were found among the different lines. Values are mean ± SEM.</ce:simple-para><ce:simple-para view="extended" id="fspara0200">(E) PSD95 puncta on dendrites of PGRN S116X neurons. Scale bar: 5 μm.</ce:simple-para></ce:caption><ce:link locator="figs2"/></ce:figure><ce:figure id="figs3"><ce:label>Figure S3</ce:label><ce:caption><ce:simple-para view="extended" id="fspara0205">PGRN Levels in iPSC-Derived Microglia, Related to <ce:cross-ref refid="fig3">Figure 3</ce:cross-ref></ce:simple-para><ce:simple-para view="extended" id="fspara0210">(A) Phase-contrast images of the cells at different stages of the microglia differentiation.</ce:simple-para><ce:simple-para view="extended" id="fspara0215">(B) Phase-contrast and respective immunostaining for the microglia marker Iba1. Scale bar: 50 μm.</ce:simple-para><ce:simple-para view="extended" id="fspara0220">(C) <ce:italic>GRN</ce:italic> mRNA expression in microglia derived from PGRN S116X iPSCs (lines 1 and 26) relative to that in microglia derived from control iPSCs (lines 17 and 20). As in iPSCs and neurons, PGRN levels were 50% lower in PGRN S116X microglia. Values are mean ± SEM.</ce:simple-para><ce:simple-para view="extended" id="fspara0225">(D) PGRN secreted into the medium over 24 hr of microglia derived from control, sporadic, and PGRN S116X iPSCs. The average of values for control lines was set to 100%. Values are mean ± SEM.</ce:simple-para><ce:simple-para view="extended" id="fspara0230">(E) Intracellular PGRN in microglia derived from control, sporadic, and PGRN S116X iPSCs. The average of values for control lines was set to 100%. Values are mean ± SEM.</ce:simple-para></ce:caption><ce:link locator="figs3"/></ce:figure><ce:figure id="figs4"><ce:label>Figure S4</ce:label><ce:caption><ce:simple-para view="extended" id="fspara0235">Effects of Stress Inducers on iPSC-derived Neurons, Related to <ce:cross-ref refid="fig4">Figure 4</ce:cross-ref></ce:simple-para><ce:simple-para view="extended" id="fspara0240">(A-C and E) The viability of cells incubated with rotenone (A), hydrogen peroxide (B), lactacystin (C), PD98059 (E), or DMSO for 24 hr was assessed with the WST-1 assay. Values are mean ± SEM. <ce:sup loc="pre">∗</ce:sup>p &lt; 0.05, <ce:sup loc="pre">∗∗∗</ce:sup>p &lt; 0.001.</ce:simple-para><ce:simple-para view="extended" id="fspara0245">(D) Immunofluorescence analysis of the percentage of iPSC-derived neurons with translocated TDP-43 from the nucleus to the cytoplasm after exposure to 10 nM staurosporine, 0.5 μM tunicamycin, or DMSO for 24 hr. MAP2<ce:sup loc="post">+</ce:sup> cells showing TDP43 outside the nuclei were scored. On average, 200 cells were analyzed per experiment (n = 3 independent cultures).</ce:simple-para><ce:simple-para view="extended" id="fspara0250">(F) <ce:italic>RPS6KB2</ce:italic> mRNA expression levels in control, sporadic, and PGRN S116X neurons.</ce:simple-para><ce:simple-para view="extended" id="fspara0255">(G) Restoration of the expression level of the gene <ce:italic>RPS6KB2</ce:italic> by PGRN expression in PGRN S116X neurons. Values are mean ± SEM. <ce:sup loc="pre">∗</ce:sup>p &lt; 0.05, <ce:sup loc="pre">∗∗</ce:sup>p &lt; 0.01.</ce:simple-para><ce:simple-para view="extended" id="fspara0260">(H) Ingenuity pathway analysis. The network resulting from the differentially expressed genes between PGRN S116X neurons and control neurons shows genes in the MAPK signaling pathway. Gene symbols are color-coded according to their fold change (red, upregulated genes; green, downregulated genes).</ce:simple-para><ce:simple-para view="extended" id="fspara0265">(I) Cell-survival pathways affected by PGRN deficiency in patient-specific human neurons. The strategy of probing signaling pathways with different inhibitors is shown.</ce:simple-para></ce:caption><ce:link locator="figs4"/></ce:figure></ce:floats><head><ce:dochead><ce:textfn>Report</ce:textfn></ce:dochead><ce:title>Induced Pluripotent Stem Cell Models of Progranulin-Deficient Frontotemporal Dementia Uncover Specific Reversible Neuronal Defects</ce:title><ce:author-group><ce:author><ce:given-name>Sandra</ce:given-name><ce:surname>Almeida</ce:surname><ce:cross-ref refid="aff1"><ce:sup loc="post">1</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Zhijun</ce:given-name><ce:surname>Zhang</ce:surname><ce:cross-ref refid="aff1"><ce:sup loc="post">1</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Giovanni</ce:given-name><ce:surname>Coppola</ce:surname><ce:cross-ref refid="aff3"><ce:sup loc="post">3</ce:sup></ce:cross-ref><ce:cross-ref refid="fn1"><ce:sup loc="post">7</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Wenjie</ce:given-name><ce:surname>Mao</ce:surname><ce:cross-ref refid="aff2"><ce:sup loc="post">2</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Kensuke</ce:given-name><ce:surname>Futai</ce:surname><ce:cross-ref refid="aff2"><ce:sup loc="post">2</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Anna</ce:given-name><ce:surname>Karydas</ce:surname><ce:cross-ref refid="aff4"><ce:sup loc="post">4</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Michael D.</ce:given-name><ce:surname>Geschwind</ce:surname><ce:cross-ref refid="aff4"><ce:sup loc="post">4</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>M. Carmela</ce:given-name><ce:surname>Tartaglia</ce:surname><ce:cross-ref refid="aff4"><ce:sup loc="post">4</ce:sup></ce:cross-ref><ce:cross-ref refid="fn2"><ce:sup loc="post">8</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Fuying</ce:given-name><ce:surname>Gao</ce:surname><ce:cross-ref refid="aff3"><ce:sup loc="post">3</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Davide</ce:given-name><ce:surname>Gianni</ce:surname><ce:cross-ref refid="aff1"><ce:sup loc="post">1</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Miguel</ce:given-name><ce:surname>Sena-Esteves</ce:surname><ce:cross-ref refid="aff1"><ce:sup loc="post">1</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Daniel H.</ce:given-name><ce:surname>Geschwind</ce:surname><ce:cross-ref refid="aff3"><ce:sup loc="post">3</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Bruce L.</ce:given-name><ce:surname>Miller</ce:surname><ce:cross-ref refid="aff2"><ce:sup loc="post">2</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Robert V.</ce:given-name><ce:surname>Farese</ce:surname><ce:suffix>Jr.</ce:suffix><ce:cross-ref refid="aff5"><ce:sup loc="post">5</ce:sup></ce:cross-ref><ce:cross-ref refid="aff6"><ce:sup loc="post">6</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Fen-Biao</ce:given-name><ce:surname>Gao</ce:surname><ce:cross-ref refid="aff1"><ce:sup loc="post">1</ce:sup></ce:cross-ref><ce:cross-ref refid="cor1"><ce:sup loc="post">∗</ce:sup></ce:cross-ref><ce:e-address type="email">fen-biao.gao@umassmed.edu</ce:e-address></ce:author><ce:affiliation id="aff1"><ce:label>1</ce:label><ce:textfn>Department of Neurology, University of Massachusetts Medical School, Worcester, MA 01605, USA</ce:textfn></ce:affiliation><ce:affiliation id="aff2"><ce:label>2</ce:label><ce:textfn>Brudnick Neuropsychiatric Research Institute, Department of Psychiatry, University of Massachusetts Medical School, Worcester, MA 01605, USA</ce:textfn></ce:affiliation><ce:affiliation id="aff3"><ce:label>3</ce:label><ce:textfn>Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA</ce:textfn></ce:affiliation><ce:affiliation id="aff4"><ce:label>4</ce:label><ce:textfn>Memory and Aging Center, Department of Neurology, University of California, San Francisco, CA 94143, USA</ce:textfn></ce:affiliation><ce:affiliation id="aff5"><ce:label>5</ce:label><ce:textfn>Gladstone Institute of Cardiovascular Disease, San Francisco, CA 94158, USA</ce:textfn></ce:affiliation><ce:affiliation id="aff6"><ce:label>6</ce:label><ce:textfn>Departments of Medicine and Biochemistry and Biophysics, University of California, San Francisco, CA 94158, USA</ce:textfn></ce:affiliation><ce:correspondence id="cor1"><ce:label>∗</ce:label><ce:text>Corresponding author</ce:text></ce:correspondence><ce:footnote id="fn1"><ce:label>7</ce:label><ce:note-para>Present address: Departments of Psychiatry and Neurology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA</ce:note-para></ce:footnote><ce:footnote id="fn2"><ce:label>8</ce:label><ce:note-para>Present address: Krembil Neuroscience Centre and Department of Neurology, University of Toronto, Toronto, Canada</ce:note-para></ce:footnote></ce:author-group><ce:date-received day="30" month="1" year="2012"/><ce:date-revised day="21" month="8" year="2012"/><ce:date-accepted day="10" month="9" year="2012"/><ce:miscellaneous>Published online: October 11, 2012</ce:miscellaneous><ce:abstract class="author"><ce:section-title>Summary</ce:section-title><ce:abstract-sec><ce:simple-para id="abspara0010" view="all">The pathogenic mechanisms of frontotemporal dementia (FTD) remain poorly understood. Here we generated multiple induced pluripotent stem cell lines from a control subject, a patient with sporadic FTD, and an FTD patient with a novel heterozygous <ce:italic>GRN</ce:italic> mutation (progranulin [PGRN] S116X). In neurons and microglia differentiated from PGRN S116X induced pluripotent stem cells, the levels of intracellular and secreted PGRN were reduced, establishing patient-specific cellular models of PGRN haploinsufficiency. Through a systematic screen of inducers of cellular stress, we found that PGRN S116X neurons, but not sporadic FTD neurons, exhibited increased sensitivity to staurosporine and other kinase inhibitors. Moreover, the serine/threonine kinase S6K2, a component of the phosphatidylinositol 3-kinase and mitogen-activated protein kinase pathways, was specifically downregulated in PGRN S116X neurons. Both increased sensitivity to kinase inhibitors and reduced S6K2 were rescued by PGRN expression. Our findings identify cell-autonomous, reversible defects in patient neurons with PGRN deficiency, and provide a compelling model for studying PGRN-dependent pathogenic mechanisms and testing potential therapies.</ce:simple-para></ce:abstract-sec></ce:abstract><ce:abstract class="graphical"><ce:abstract-sec><ce:section-title>Graphical Abstract</ce:section-title><ce:simple-para id="abspara0015" view="all"><ce:display><ce:figure id="undfig1"><ce:link locator="fx1"/></ce:figure></ce:display></ce:simple-para></ce:abstract-sec><ce:abstract-sec><ce:section-title>Highlights</ce:section-title><ce:simple-para id="abspara0020" view="all">► A human neuron model of progranulin (PGRN) haploinsufficiency is established ► Sporadic and PGRN-deficient frontotemporal dementia patient iPSCs are made ► PGRN S116X mutant neurons are sensitive to stress by kinase inhibitors ► S6K2 is downregulated in patient neurons in a PGRN-dependent manner</ce:simple-para></ce:abstract-sec></ce:abstract><ce:abstract class="teaser"><ce:abstract-sec><ce:simple-para id="abspara0025" view="all">Progranulin (PGRN) mutations are a common cause of frontotemporal dementia, but the underlying molecular mechanism is unknown. Gao and colleagues now generate multiple frontotemporal dementia patient-specific induced pluripotent stem cell lines and establish a human neuronal model of PGRN haploinsufficiency. Studies on human postmitotic neurons derived from these lines reveal cell-autonomous and reversible defects in specific signaling pathways that are compromised in PGRN-deficient neurons and establish a model system for studying PGRN-dependent pathogenic mechanisms and testing potential therapies.</ce:simple-para></ce:abstract-sec></ce:abstract></head><body view="all"><ce:sections><ce:section id="sec1" view="all"><ce:section-title>Introduction</ce:section-title><ce:para id="p0010" view="all">Frontotemporal dementia (FTD), the second most common form of presenile dementia before the age of 65, is associated with focal atrophy of the frontal or temporal lobes and deficits in cognition, behavior, and language (<ce:cross-ref refid="bib3">Boxer and Miller, 2005</ce:cross-ref>). Mutations that cause FTD have been identified in several genes, including those encoding valosin-containing protein (VCP; <ce:cross-ref refid="bib35">Watts et al., 2004</ce:cross-ref>), charged multivesicular body protein 2B (CHMP2B; <ce:cross-ref refid="bib30">Skibinski et al., 2005</ce:cross-ref>), progranulin (PGRN; <ce:cross-ref refid="bib2">Baker et al., 2006</ce:cross-ref>; <ce:cross-ref refid="bib8">Cruts et al., 2006</ce:cross-ref>), and chromosome 9 open reading frame 72 (C9ORF72; <ce:cross-ref refid="bib9">DeJesus-Hernandez et al., 2011</ce:cross-ref>; <ce:cross-ref refid="bib28">Renton et al., 2011</ce:cross-ref>). It is not known how these diverse mutations cause similar clinical manifestations, and no effective treatment is available.</ce:para><ce:para id="p0015" view="all">The secreted glycoprotein PGRN has been implicated in cell growth and survival, inflammation, synaptic functions, and other cellular functions (<ce:cross-ref refid="bib17">He and Bateman, 2003</ce:cross-ref>; <ce:cross-ref refid="bib38">Yin et al., 2010</ce:cross-ref>; <ce:cross-ref refid="bib32">Tapia et al., 2011</ce:cross-ref>). Although most (if not all) pathogenic mutations in <ce:italic>GRN</ce:italic> lead to pathological changes in FTD due to PGRN haploinsufficiency (<ce:cross-ref refid="bib2">Baker et al., 2006</ce:cross-ref>; <ce:cross-ref refid="bib8">Cruts et al., 2006</ce:cross-ref>), the underlying molecular mechanism is unknown. PGRN mutations are a common cause of FTD. However, no robust pathological phenotype has been found in <ce:italic>Grn</ce:italic><ce:sup loc="post">+/-</ce:sup> mice, and selective neuronal cell loss is limited even in <ce:italic>Grn</ce:italic> knockout mice (<ce:cross-ref refid="bib1">Ahmed et al., 2010</ce:cross-ref>; <ce:cross-ref refid="bib16">Ghoshal et al., 2012</ce:cross-ref>; <ce:cross-ref refid="bib25">Petkau et al., 2012</ce:cross-ref>; <ce:cross-ref refid="bib38">Yin et al., 2010</ce:cross-ref>). Thus, a more suitable model for dissecting the pathogenic mechanisms that underlie PGRN haploinsufficiency is needed.</ce:para><ce:para id="p0020" view="all">The ability to generate human induced pluripotent stem cells (iPSCs) offers an unprecedented opportunity to analyze the molecular consequences of pathogenic mutations in the context of the unique genetic background of individual patients (<ce:cross-ref refid="bib37">Yamanaka, 2007</ce:cross-ref>). Indeed, iPSCs have been generated from patients with different neurodegenerative diseases (e.g., <ce:cross-ref refid="bib11">Dimos et al., 2008</ce:cross-ref>; <ce:cross-ref refid="bib12">Ebert et al., 2009</ce:cross-ref>; <ce:cross-ref refid="bib31">Soldner et al., 2009</ce:cross-ref>; <ce:cross-ref refid="bib23">Nguyen et al., 2011</ce:cross-ref>; <ce:cross-ref refid="bib19">Israel et al., 2012</ce:cross-ref>). In this study, we generated multiple FTD-patient-specific iPSC lines and established a human neuronal model of PGRN haploinsufficiency. From studies of human postmitotic neurons derived from these lines, we identify cell-autonomous and reversible defects in specific signaling pathways that are compromised in PGRN-deficient neurons.</ce:para></ce:section><ce:section id="sec2" view="all"><ce:section-title>Results</ce:section-title><ce:section id="sec2.1" view="all"><ce:section-title>Generation and Characterization of FTD-Patient-Specific iPSCs</ce:section-title><ce:para id="p0025" view="all">The two FTD patients under investigation in this study were part of a longitudinal dementia research program at the Memory and Aging Center, University of California, San Francisco. Both had an 8-year history of behavioral changes and memory impairment at the time of tissue collection for this study. One patient, a 67-year-old male with sporadic FTD, tested negative for mutations in <ce:italic>GRN</ce:italic>, <ce:italic>MAPT</ce:italic>, and <ce:italic>C9ORF72</ce:italic>. The other patient, a 64-year-old male with a significant family history of dementia, had behavioral variant FTD. MRI in this patient demonstrated severe bifrontal and temporal atrophy associated with gliosis in the frontal lobes (greater on the right). One year later, MRI scans showed progression of atrophy and gliosis. Genetic testing revealed a novel nonsense mutation in <ce:italic>GRN</ce:italic>, p.S116X (g.4627C &gt; A, c.347C &gt; A), which is predicted to result in a premature stop codon. Both FTD patients had parkinsonism, which is typical of all FTD patients with PGRN mutations. An age-matched subject, a clinically normal 64-year-old male with no mutations in <ce:italic>GRN</ce:italic>, <ce:italic>MAPT</ce:italic>, or <ce:italic>C9ORF72</ce:italic>, served as a control.</ce:para><ce:para id="p0030" view="all">Skin biopsies from the upper right thigh were obtained from all three subjects, and primary fibroblasts were derived. After expansion, the fibroblasts were reprogrammed with four transcription factors (OCT3/4, SOX2, KLF4, and CMYC) into putative pluripotent stem cells as previously described (<ce:cross-ref refid="bib33">Takahashi et al., 2007</ce:cross-ref>). Approximately 5 weeks after viral transduction, &gt;50 iPSC colonies per subject were selected on the basis of their embryonic stem cell (ESC)-like morphology and expanded further on feeder cells.</ce:para><ce:para id="p0035" view="all">To identify lines in which the exogenous reprogramming factors were completely silenced, we characterized 10-15 putative iPSC lines from each subject by quantitative RT-PCR (qRT-PCR). Complete transgene silencing was achieved when the total expression of each reprogramming factor did not differ from that of the endogenous gene (<ce:cross-ref refid="fig1">Figures 1</ce:cross-ref><ce:float-anchor refid="fig1"/>A-1C). This assay allows us to detect transgene expression levels of at least 20-fold above than the endogenous levels in ESC H9 cells. Based on this analysis, we selected three lines per subject for further characterization: control lines 16, 17, and 20 (<ce:cross-ref refid="fig1">Figure 1</ce:cross-ref>A); sporadic FTD lines 9, 12, and 23 (<ce:cross-ref refid="fig1">Figure 1</ce:cross-ref>B); and PGRN S116X lines 1, 14, and 26 (<ce:cross-ref refid="fig1">Figure 1</ce:cross-ref>C). The total expression of each reprogramming factor was not different from that of the endogenous gene (<ce:cross-ref refid="fig1">Figures 1</ce:cross-ref>A-1C), indicating complete transgene silencing. All lines expressed marker genes of undifferentiated ESCs, such as <ce:italic>OCT3/4</ce:italic>, <ce:italic>SOX2</ce:italic>, and <ce:italic>NANOG</ce:italic>, at levels comparable to those in ESC line H9. Two additional stem cell markers, teratocarcinoma-derived growth factor 1 (TDGF1, or CRIPTO) and zinc finger protein 42 (ZFP42, or Rex1), were also expressed at levels equivalent to those in H9 cells (<ce:cross-ref refid="figs1">Figure S1</ce:cross-ref><ce:float-anchor refid="figs1"/>A).</ce:para><ce:para id="p0040" view="all">Sequencing confirmed that the PGRN S116X iPSC lines retained the <ce:italic>GRN</ce:italic> nonsense mutation (g.4627C &gt; A, c.347C &gt; A; <ce:cross-ref refid="fig1">Figure 1</ce:cross-ref>D). Analysis of the <ce:italic>OCT4</ce:italic> promoter region showed that undifferentiated iPSCs were hypomethylated relative to the respective fibroblasts from which they were derived (<ce:cross-ref refid="fig1">Figure 1</ce:cross-ref>E). In addition, iPSCs expressed the stem-cell-specific surface proteins SSEA4, TRA-1-60, TRA-1-81, NANOG, and OCT4, as shown by immunostaining (<ce:cross-ref refid="fig1">Figures 1</ce:cross-ref>F and <ce:cross-ref refid="figs1">S1</ce:cross-ref>B). All nine iPSC lines maintained a normal karyotype after reprogramming (<ce:cross-ref refid="fig1">Figures 1</ce:cross-ref>F and <ce:cross-ref refid="figs1">S1</ce:cross-ref>C) and could spontaneously differentiate into cell types of all three germ layers in vitro (<ce:cross-ref refid="fig1">Figures 1</ce:cross-ref>G and <ce:cross-ref refid="figs1">S1</ce:cross-ref>C). Moreover, representative iPSC lines from the subjects (control line 20, sporadic line 9, and PGRN S116X line 26) transplanted into severe combined immunodeficiency (SCID) mice gave rise to teratomas in vivo (<ce:cross-ref refid="fig1">Figure 1</ce:cross-ref>G). These findings confirm the successful reprogramming and generation of FTD-patient-specific iPSC lines, and demonstrate that these lines are similar to those in controls in terms of both their expression of stem cell markers and their pluripotency.</ce:para></ce:section><ce:section id="sec2.2" view="all"><ce:section-title>Differentiation of FTD-Patient-Specific iPSCs into Neurons</ce:section-title><ce:para id="p0045" view="all">Next, we differentiated three fully reprogrammed iPSC lines at passages 20-26 from each subject into postmitotic neurons, using a protocol available in our lab (<ce:cross-ref refid="bib10">Delaloy et al., 2010</ce:cross-ref>). The differentiation starts with neural induction, which is followed by expansion of the neural progenitor cells and neural maturation. The first step, induction of multilineage differentiation and embryoid body (EB) formation, was inefficient when iPSCs were maintained on feeder cells. Adaptation of iPSCs to feeder-free conditions allowed robust and reliable formation of EBs (<ce:cross-ref refid="fig2">Figures 2</ce:cross-ref>A and 2B<ce:float-anchor refid="fig2"/>). After 5-6 days in suspension, neural induction was initiated with basic fibroblast growth factor and N2 supplement, and rosettes (elongated cells arranged in circular structures) appeared (<ce:cross-ref refid="fig2">Figure 2</ce:cross-ref>C). Ten days later, the rosettes were isolated, expanded in suspension as neurospheres for 3-4 weeks (<ce:cross-ref refid="fig2">Figure 2</ce:cross-ref>D), and dissociated into single cells. Terminal differentiation was induced with glial-cell-line-derived neurotrophic factor, brain-derived neurotrophic factor, ascorbic acid, and cyclic AMP. Two weeks later, the cells displayed typical neuronal morphology (<ce:cross-ref refid="fig2">Figure 2</ce:cross-ref>F). Both FTD and control iPSCs differentiated at similar rates.</ce:para><ce:para id="p0050" view="all">We then sought to determine whether the disease and/or the mutation affected the percentage of neurons obtained with this protocol. After 2 weeks, ∼80% of cells in culture were positive for the neuronal marker microtubule-associated protein 2 (MAP2) and had neuronal morphology (<ce:cross-ref refid="fig2">Figure 2</ce:cross-ref>G), and &lt;4% of cells were positive for the glial marker glial fibrillary acidic protein, regardless of the genetic mutation of the iPSC line used (<ce:cross-ref refid="fig2">Figures 2</ce:cross-ref>G and 2K). Thus, the PGRN S116X mutation did not affect the percentage of neurons generated with the differentiation protocol. Approximately 40% of the MAP2<ce:sup loc="post">+</ce:sup> cells were presumably glutamatergic and expressed VGLUT1 (<ce:cross-ref refid="fig2">Figure 2</ce:cross-ref>H), and &lt;10% of cells were GABA<ce:sup loc="post">+</ce:sup> inhibitory neurons or tyrosine hydroxylase (TH)<ce:sup loc="post">+</ce:sup> dopaminergic neurons (<ce:cross-ref refid="fig2">Figures 2</ce:cross-ref>I and 2J). Again, the percentages of neurons differentiated from control and FTD-patient-specific iPSC lines were indistinguishable. Additional analysis at the messenger RNA (mRNA) level indicative of glutamatergic (<ce:italic>VGLUT1</ce:italic>), GABAergic (<ce:italic>GAD67</ce:italic>) and dopaminergic (<ce:italic>TH</ce:italic>) neuronal subtypes or postsynaptic density (<ce:italic>PSD95</ce:italic>) detected no significant differences across the different lines (<ce:cross-ref refid="figs2">Figures S2</ce:cross-ref><ce:float-anchor refid="figs2"/>A-S2D). Thus, the PGRN S116X mutation did not affect neural differentiation of iPSCs into specific type of neurons.</ce:para><ce:para id="p0055" view="all">We next performed whole-cell voltage-clamp recordings and measured membrane properties and synaptic transmission on neurons differentiated from two iPSC lines (control line 20 and PGRN S116X line 26; <ce:cross-ref refid="fig2">Figures 2</ce:cross-ref>L-2N). Most cells in culture were capable of inducing tetrodotoxin-sensitive action potentials (control: 79.2%; PGRN S116X: 75%), which is consistent with the finding that ∼80% of cells are MAP2-positive neurons (<ce:cross-ref refid="fig2">Figure 2</ce:cross-ref>G). The resting membrane potential between two cell lines does not show a statistically significant difference (control neurons: -62.5 ± 1.5 mV; PGRN S116X: -60.0 ± 1.9 mV; n = 24, p = 0.17). To address whether these cells can form functional synaptic connections, we found that PSD95 puncta were present on dendrites of these neurons (<ce:cross-ref refid="figs2">Figure S2</ce:cross-ref>E), and also measured AMPA-type glutamate receptor-mediated miniature excitatory postsynaptic currents (mEPSCs). Neurons differentiated from PGRN S116X iPSCs showed synaptic connections indistinguishable from those of control neurons (mEPSC amplitude of control neurons: 12.1 ± 1.7 pA, PGRN S116X: 14.37 ± 1.7 pA, p = 0.36; frequency of control neurons: 3.2 ± 0.6 pA, PGRN S116X: 2.2 ± 0.2 pA, n = 10, p = 0.12). These results indicate that postmitotic neurons differentiated from control and PGRN S116X iPSCs are functional.</ce:para></ce:section><ce:section id="sec2.3" view="all"><ce:section-title>A Human Neuronal Model of PGRN Haploinsufficiency</ce:section-title><ce:para id="p0060" view="all">To establish a human neuronal model of PGRN haploinsufficiency, we first examined the expression levels of PGRN in fibroblasts from each subject by qRT-PCR. <ce:italic>GRN</ce:italic> mRNA levels were similar in cells from the control subject and sporadic FTD patient (<ce:cross-ref refid="fig3">Figure 3</ce:cross-ref><ce:float-anchor refid="fig3"/>A), but in cells from the FTD patient with the PGRN S116X mutation, the mRNA level was only ∼30% of that found in the control (<ce:cross-ref refid="fig3">Figure 3</ce:cross-ref>A). This observation is consistent with the substantially lower average plasma PGRN levels in FTD patients harboring <ce:italic>GRN</ce:italic> mutations compared with those without such mutations (<ce:cross-ref refid="bib7">Coppola et al., 2008</ce:cross-ref>; <ce:cross-ref refid="bib15">Finch et al., 2009</ce:cross-ref>). However, after reprogramming, the <ce:italic>GRN</ce:italic> mRNA was 50% lower in all three PGRN S116X iPSC lines (<ce:cross-ref refid="fig3">Figure 3</ce:cross-ref>B), as expected. Moreover, the relative expression levels of <ce:italic>GRN</ce:italic> mRNA in all control or sporadic FTD iPSCs showed little variation (<ce:cross-ref refid="fig3">Figure 3</ce:cross-ref>B). Correspondingly, PGRN S116X iPSCs secreted 50% less PGRN than iPSCs from the control subject and sporadic FTD patient (<ce:cross-ref refid="fig3">Figure 3</ce:cross-ref>C).</ce:para><ce:para id="p0065" view="all">Upon differentiation, <ce:italic>GRN</ce:italic> mRNA levels were ∼41% lower in PGRN S116X neurons than in control and sporadic FTD neurons differentiated from multiple iPSC lines (<ce:cross-ref refid="fig3">Figure 3</ce:cross-ref>D). The levels of both intracellular and secreted PGRN in these neurons were also correspondingly reduced, as measured by ELISA (<ce:cross-ref refid="fig3">Figures 3</ce:cross-ref>E and 3F). Thus, we established a patient-specific human neuronal model of PGRN haploinsufficiency. We were also able to differentiate these iPSCs into microglia as shown by expression of the microglia-specific marker Iba1 (<ce:cross-ref refid="figs3">Figures S3</ce:cross-ref><ce:float-anchor refid="figs3"/>A and S3B). PGRN secretion from these cells was also ∼50% lower than in control and sporadic FTD cells (<ce:cross-ref refid="figs3">Figures S3</ce:cross-ref>C and S3D).</ce:para></ce:section><ce:section id="sec2.4" view="all"><ce:section-title>PGRN S116X Neurons Are More Sensitive to Cellular Stress Induced by Inhibitors of the Phosphatidylinositol 3-Kinase/Akt and MEK/Mitogen-Activated Protein Kinase Signaling Pathways</ce:section-title><ce:para id="p0070" view="all">Compared with many other neurodegenerative diseases, the cellular defects associated with FTD remain poorly defined. Human neurons derived from patient-specific iPSCs are an excellent system in which to examine disease-gene-specific cellular phenotypes. To conduct such an examination, we first used two iPSC lines from each patient and differentiated them into postmitotic neurons. Under normal culture conditions, PGRN S116X and control neurons show similar viability. As a late-onset disease, FTD likely results from damage that accumulates over time rather than from an acute effect of the reduced PGRN levels. Very little is known about the cellular defects caused by PGRN haploinsufficiency in human neurons. Thus, to identify pathways that might be compromised in PGRN S116X neurons, we performed a systematic screen with a variety of inducers of cellular stress that affect different key cellular functions/pathways, such as mitochondria, oxidative stress, endoplasmic reticulum (ER), proteasome, and cell survival. Neurons derived from the healthy individual and the sporadic FTD patient were used as controls.</ce:para><ce:para id="p0075" view="all">We tested two well-known inducers of mitochondrial dysfunction, oligomycin (an ATP synthase inhibitor) and rotenone (a complex I inhibitor), as well as a classical inducer of oxidative stress (hydrogen peroxide). All three inducers of cell stress reduced cell viability in a dose-dependent manner, and all genotypes or disease states were equally affected (<ce:cross-ref refid="figs4">Figures S4</ce:cross-ref><ce:float-anchor refid="figs4"/>A and S4B; due to space limitations, data on oligomycin not shown). In contrast, PGRN S116X neurons were more susceptible than control neurons to ER stress induced by tunicamycin, an inhibitor of protein N-glycosylation (<ce:cross-ref refid="fig4">Figure 4</ce:cross-ref><ce:float-anchor refid="fig4"/>A), and proteasome activity inhibition induced by lactacystin (<ce:cross-ref refid="figs4">Figure S4</ce:cross-ref>C). Because sporadic FTD neurons also showed similar enhanced sensitivity to tunicamycin and lactacystin (<ce:cross-ref refid="fig4">Figures 4</ce:cross-ref>A and <ce:cross-ref refid="figs4">S4</ce:cross-ref>C), we concluded that these cellular phenotypes are not specific to PGRN deficiency.</ce:para><ce:para id="p0080" view="all">To further explore PGRN-dependent cellular defects in FTD neurons, we also tested the effect of staurosporine, a broad-spectrum kinase inhibitor that induces apoptosis (<ce:cross-ref refid="fig4">Figure 4</ce:cross-ref>B). Interestingly, PGRN S116X neurons were more sensitive to staurosporine than control or sporadic FTD neurons (<ce:cross-ref refid="fig4">Figure 4</ce:cross-ref>B). This finding suggests that PGRN deficiency affects kinase pathways involved in cell survival, causing them to be more susceptible to inhibition of such pathways.</ce:para><ce:para id="p0085" view="all">To validate the findings of the cell viability assay, we also measured the activation of caspase-3, a well-studied mediator of apoptotic cell death. Consistent with the results of the cell viability assay, PGRN S116X neurons showed greater caspase-3 activation in response to staurosporine than control or sporadic FTD neurons, whereas tunicamycin increased caspase-3 activity in both PGRN S116X and sporadic FTD neurons (<ce:cross-ref refid="fig4">Figure 4</ce:cross-ref>D). Because TDP-43 pathology is a hallmark in the brains of FTD patients with PGRN deficiency (<ce:cross-ref refid="bib22">Neumann et al., 2006</ce:cross-ref>), and increased caspase-3 activity leads to enhanced cleavage and mislocalization of TDP-43 (<ce:cross-ref refid="bib40">Zhang et al., 2007</ce:cross-ref>), we also analyzed the cellular distribution of TDP-43 under stress to confirm our initial findings. After exposure to staurosporine, the percentage of neurons with redistribution of TDP-43 from the nucleus to the cytoplasm was significantly higher in PGRN S116X neurons than in control or sporadic FTD neurons (<ce:cross-ref refid="figs4">Figure S4</ce:cross-ref>D). In contrast, tunicamycin resulted in similar increases in the percentages of PGRN S116X and sporadic neurons with cytoplasmic TDP-43. Interestingly, in the absence of a stress inducer, the percentage of PGRN S116X neurons with cytoplasmic TDP-43 was higher than in control or sporadic FTD neurons (<ce:cross-ref refid="figs4">Figure S4</ce:cross-ref>D). Thus, both the caspase-3 and TDP-43 assays confirm the intrinsic vulnerability of PGRN S116X neurons under stress.</ce:para><ce:para id="p0090" view="all">Because staurosporine is a broad-spectrum kinase inhibitor that affects several signaling pathways, we next tested more specific kinase inhibitors to identify specific pathways affected by reduced PGRN levels. PGRN S116X neurons were more susceptible than control or sporadic FTD neurons to wortmannin (<ce:cross-ref refid="fig4">Figure 4</ce:cross-ref>C) and LY294002 (data not shown), two phosphatidylinositol 3-kinase (PI3K) inhibitors, and PD98059, an MEK inhibitor (<ce:cross-ref refid="figs4">Figure S4</ce:cross-ref>E). These findings suggest that PGRN deficiency impairs the PI3K/Akt and MEK/mitogen-activated protein kinase (MAPK) signaling pathways in human neurons.</ce:para></ce:section><ce:section id="sec2.5" view="all"><ce:section-title>The Cellular and Molecular Defects of PGRN S116X Neurons Can be Rescued by PGRN Expression</ce:section-title><ce:para id="p0095" view="all">We next examined the causal relationship between PGRN haploinsufficiency and enhanced sensitivity to cellular stress induced by inhibitors of the PI3K/Akt and MEK/MAPK pathways in PGRN S116X neurons. To that end, we used a CS-CW-GRN-IG lentiviral vector to express PGRN in most (if not all) of the human neurons in culture. The decreased cell viability (<ce:cross-ref refid="fig4">Figure 4</ce:cross-ref>E) in staurosporine-treated PGRN S116X neurons was rescued by PGRN expression. A similar result was obtained when increased caspase-3 activation was used as the assay (<ce:cross-ref refid="fig4">Figure 4</ce:cross-ref>F), confirming the validity of the cell viability assay. In contrast, the increased sensitivity of PGRN S116X neurons to the ER stress induced by tunicamycin was not rescued by PGRN expression (<ce:cross-ref refid="fig4">Figure 4</ce:cross-ref>E). More importantly, the increased sensitivity of PGRN S116X neurons to inhibitors of the PI3K/Akt and MEK/MAPK pathways was also rescued (<ce:cross-ref refid="fig4">Figure 4</ce:cross-ref>E). Thus, the novel cellular defects of PGRN S116X neurons uncovered under stress are specific to PGRN deficiency.</ce:para><ce:para id="p0100" view="all">Next, we sought to identify misregulated components in the PI3K/Akt and MEK/MAPK pathways by performing gene expression analyses on two to three replicate neuron cultures differentiated from each iPSC line and four iPSC lines per individual (30 samples total). We compared PGRN S116X neurons and sporadic FTD neurons versus control neurons, and identified a number of differentially expressed genes, both shared between PGRN S116X and sporadic FTD neurons, and specific to PGRN S116X neurons (<ce:cross-ref refid="fig4">Figure 4</ce:cross-ref>G). In addition, a clustering analysis showed that the gene expression patterns in neurons differentiated from three separate iPSC lines of the same individual were remarkably similar to each other (<ce:cross-ref refid="fig4">Figure 4</ce:cross-ref>G).</ce:para><ce:para id="p0105" view="all">Among the top downregulated genes in PGRN S116X neurons (but not in control or sporadic FTD neurons) was the ribosomal protein S6 kinase beta-2 (<ce:italic>RPS6KB2</ce:italic>; <ce:cross-ref refid="fig4">Figure 4</ce:cross-ref>H). This gene encodes S6K2, a member of the S6 kinase family of serine/threonine kinases that has been shown to play an important role in both the PI3K/Akt and MEK/MAPK signaling pathways (<ce:cross-ref refid="bib13">Fenton and Gout, 2011</ce:cross-ref>), and is part of a coordinated network of differentially expressed genes, including <ce:italic>GRN</ce:italic> (<ce:cross-ref refid="figs4">Figure S4</ce:cross-ref>H). The downregulation of the <ce:italic>RPS6KB2</ce:italic> gene was confirmed by qRT-PCR (<ce:cross-ref refid="figs4">Figure S4</ce:cross-ref>F) and its mRNA could be restored to wild-type level by PGRN expression (<ce:cross-ref refid="figs4">Figure S4</ce:cross-ref>G). More importantly, S6K2 protein level is reduced by ∼50% in PGRN S116X neurons, which can be rescued to wild-type level by PGRN expression (<ce:cross-ref refid="fig4">Figures 4</ce:cross-ref>I and 4J). Taken together, these studies reveal novel cellular and molecular defects of PGRN S116X neurons in the PI3K/Akt and MEK/MAPK signaling pathways, which can be rescued by PGRN expression (<ce:cross-ref refid="figs4">Figure S4</ce:cross-ref>I).</ce:para></ce:section></ce:section><ce:section id="sec3" view="all"><ce:section-title>Discussion</ce:section-title><ce:para id="p0110" view="all">PGRN haploinsufficiency is a major cause in FTD pathogenesis (<ce:cross-ref refid="bib2">Baker et al., 2006</ce:cross-ref>; <ce:cross-ref refid="bib8">Cruts et al., 2006</ce:cross-ref>). The underlying mechanism remains poorly understood, in part due to the lack of suitable model systems. Even in <ce:italic>Grn</ce:italic> knockout mice, neuronal cell loss is limited, and mechanistic studies are further complicated by the finding that PGRN levels may vary widely among patient brains in the later stages of disease (<ce:cross-ref refid="bib5">Chen-Plotkin et al., 2010</ce:cross-ref>). The iPSC-based human neuronal model of PGRN haploinsufficiency, as established in this report, provides a platform for testing small molecules that can restore PGRN levels. It also serves as a valuable and more physiologically relevant model for elucidating the mechanisms of FTD.</ce:para><ce:para id="p0115" view="all">FTD is an age-dependent neurodegenerative disease, and some intrinsic vulnerabilities of human neurons are more likely to manifest under stress conditions in culture. Indeed, this approach has been used recently to recapitulate some key features of major neurodegenerative diseases in human neurons derived from patient-specific iPSCs (e.g., <ce:cross-ref refid="bib23">Nguyen et al., 2011</ce:cross-ref>). However, in contrast to the well-studied Alzheimer disease and Parkinson disease (PD), little is known about neuronal defects in FTD patients that are caused by PGRN deficiency. Differential sensitivity of neurons to a particular stressor in culture within a short time window may reveal partially defective molecular pathways relevant to FTD pathogenesis.</ce:para><ce:para id="p0120" view="all">A previous work showed that PGRN deficiency leads to molecular alterations in apoptotic pathways and Wnt signaling (<ce:cross-ref refid="bib26">Rosen et al., 2011</ce:cross-ref>). Our data here show that PGRN S116X human neurons are more prone to reduced cell viability induced by specific protein kinase inhibitors, implicating the PI3K/Akt and MEK/MAPK signaling pathways in the molecular pathogenesis of FTD. This cellular defect is rescued by ectopic expression of PGRN in human PGRN S116X neurons, consistent with previous findings that PGRN promotes the survival of rodent primary neurons (<ce:cross-ref refid="bib34">Van Damme et al., 2008</ce:cross-ref>; <ce:cross-ref refid="bib27">Ryan et al., 2009</ce:cross-ref>; <ce:cross-ref refid="bib36">Xu et al., 2011</ce:cross-ref>) and activates the PI3K/Akt/S6K pathway in cancer cells (<ce:cross-ref refid="bib39">Zanocco-Marani et al., 1999</ce:cross-ref>). We also found that S6K2, a component in both PI3K/Akt and MEK/MAPK signaling pathways, is specifically downregulated in PGRN S116X neurons as part of a coordinated gene network, and its expression level can be restored to normal by ectopic PGRN expression. Interestingly, our reanalysis of the gene expression data published by <ce:cross-ref refid="bib4">Chen-Plotkin et al. (2008)</ce:cross-ref> revealed that <ce:italic>RPS6KB2</ce:italic> mRNA is downregulated by ∼40% in the frontal cortex, but not in the hippocampus or cerebellum, of FTD patients with PGRN mutations. Taken together, these findings reinforce the notion that the PI3K/Akt and MEK/MAPK signaling pathways are compromised in PGRN S116X neurons, and highlight the primary role PGRN plays in promoting neuronal survival.</ce:para><ce:para id="p0125" view="all">ER stress and mitochondrial impairment have both been closely linked to neurodegenerative diseases (<ce:cross-ref refid="bib20">Matus et al., 2011</ce:cross-ref>; <ce:cross-ref refid="bib29">Schon and Przedborski, 2011</ce:cross-ref>). Our finding that neither PGRN S116X nor sporadic FTD neurons show enhanced sensitivity to mitochondrial or oxidative stressors argues that these pathways are unlikely to be affected by reduced PGRN levels in cultured neurons. However, mitochondrial dysfunction and oxidative stress may develop at later stages of disease progression in FTD patients.</ce:para><ce:para id="p0130" view="all">On the other hand, both PGRN S116X and sporadic FTD neurons are more susceptible to inducers of ER stress and inhibitors of proteasome function than control neurons. This cellular defect appears to be PGRN-independent since PGRN expression levels are normal in sporadic FTD neurons. In accordance with our findings, it was recently reported that ER stress and unfolded protein response activation contribute to both sporadic FTD and familial FTD caused by <ce:italic>MAPT</ce:italic> mutations (<ce:cross-ref refid="bib24">Nijholt et al., 2012</ce:cross-ref>). Moreover, both Aβ and increased levels of phosphorylated tau induce ER stress in Alzheimer disease (e.g., <ce:cross-ref refid="bib18">Hoozemans et al., 2009</ce:cross-ref>), as does the accumulation of misfolded α-synuclein in PD (<ce:cross-ref refid="bib6">Colla et al., 2012</ce:cross-ref>). Therefore, altered ER stress responses are likely to be a general feature in a variety of neurodegenerative diseases.</ce:para><ce:para id="p0135" view="all">In summary, we have established neuronal models of human PGRN deficiency and demonstrated specific and reversible defects that affect the survival of these neurons. Our findings suggest that chronic weakening of prosurvival signaling pathways may render neurons more sensitive to environmental insults in FTD patients with PGRN deficiency. Thus, in addition to strategies to increase PGRN levels, therapeutic approaches that generally enhance neuronal survival through growth factor signaling may be beneficial in slowing disease progression in these patients.</ce:para></ce:section><ce:section id="sec4" role="materials-methods" view="all"><ce:section-title>Experimental Procedures</ce:section-title><ce:section id="sec4.1" view="all"><ce:section-title>Isolation of Primary Human Skin Fibroblasts and Generation of iPSCs</ce:section-title><ce:para id="p0140" view="all">This study was approved by the Institutional Review Board and Ethics Committees of the University of California, San Francisco, and written informed consent was obtained in all cases. The patient with the PGRN S116X mutation followed the classic clinical progression for FTD and developed parkinsonism, as do all FTD patients with PGRN mutations, but he did not show typical features of PD dementia. The patient with sporadic FTD also showed parkinsonism. Skin biopsies were collected, cut into small pieces, and placed on culture dishes to allow the fibroblasts to expand. The cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, 1X nonessential amino acids, and penicillin/streptomycin (100 U/ml). iPSCs were generated as described previously (<ce:cross-ref refid="bib33">Takahashi et al., 2007</ce:cross-ref>). Please see <ce:cross-ref refid="mmc2">Supplemental Information</ce:cross-ref> for more details.</ce:para></ce:section><ce:section id="sec4.2" view="all"><ce:section-title>qRT-PCR, Immunocytochemistry, Differentiation and Characterization of iPSCs, and Electrophysiology</ce:section-title><ce:para id="p0145" view="all">Most of the experiments involving qRT-PCR, immunocytochemistry, differentiation and characterization of iPSCs, and electrophysiology were performed as previously described (<ce:cross-ref refid="bib10">Delaloy et al., 2010</ce:cross-ref>) with minor adjustments. Please see <ce:cross-ref refid="mmc2">Supplemental Information</ce:cross-ref> for more details.</ce:para></ce:section><ce:section id="sec4.3" view="all"><ce:section-title>PGRN Measurements</ce:section-title><ce:para id="p0150" view="all">Fresh culture medium was added to the cells 24 hr before collection. After the medium was collected, the cells were washed once with phosphate-buffered saline (PBS), lysed with NP-40 buffer, and subjected to three freeze-thaw cycles. Both the culture medium and the cell lysates were centrifuged at 12,000 rpm at 4°C for 10 min to clear cellular debris. Cell lysate supernatants were assayed for protein concentration with the BioRad reagent assay. Total cell lysates and culture medium were diluted, and the PGRN levels were determined with an ELISA kit (Alexis Biochemicals, San Diego, CA) according to the manufacturer's instructions. Data were normalized to protein concentration.</ce:para></ce:section><ce:section id="sec4.4" view="all"><ce:section-title>Stress-Induced Toxicity Assay</ce:section-title><ce:para id="p0155" view="all">Two-week-old neurons were exposed for 24 hr to the following stress inducers: tunicamycin, lactacystin, rotenone, oligomycin, hydrogen peroxide, staurosporine, wortmannin, LY294002, PD98059, or DMSO. Cell viability was determined with the WST1 cell-proliferation assay (Roche Applied Science, Penzberg, Germany) according to the manufacturer's instructions. Caspase-3 activity assay is described in the <ce:cross-ref refid="mmc2">Supplemental Information</ce:cross-ref>.</ce:para></ce:section><ce:section id="sec4.5" view="all"><ce:section-title>PGRN Rescue Experiments</ce:section-title><ce:para id="p0160" view="all">Human <ce:italic>GRN</ce:italic> (NM_002087.2) was inserted into a CS-CGW lentiviral vector with Nhe I and Xho I. The vector also expressed green fluorescent protein through an internal ribosome entry site. One-week-old neurons were transduced overnight with lentivirus expressing PGRN or empty vector. The next morning, the medium was doubled and thereafter replaced every other day. One week after transduction, the neurons were exposed to 10 nM staurosporine, 0.5 μM tunicamycin, 50 μM PD98059, 75 nM wortmannin, or DMSO for 24 hr. Cells were assayed for cell viability, caspase-3 activation, and S6K2 levels. A multiplicity of infection of 50 was used in all cases.</ce:para></ce:section><ce:para view="extended" id="p0165"><ce:display><ce:textbox role="e-extra" id="dtbox1"><ce:label>Extended Experimental Procedures</ce:label><ce:textbox-body><ce:sections><ce:section id="dtbox1sec1" view="all"><ce:section-title>Generation of iPSC Lines</ce:section-title><ce:para id="p0170" view="all">Fibroblasts were seeded at 8 × 10<ce:sup loc="post">5</ce:sup> cells per 100-mm dish and transduced with equal volumes of supernatants from retroviruses encoding human <ce:italic>OCT3/4</ce:italic>, <ce:italic>SOX2</ce:italic>, <ce:italic>KLF4</ce:italic>, and <ce:italic>c-MYC</ce:italic>. The next day, the medium was removed and replaced with fresh viral supernatants. Seven days after the first infection, cells were collected and seeded (5 × 10<ce:sup loc="post">4</ce:sup> cells per 100-mm dish) onto mitomycin C-treated SNL feeder cells. One day later, the medium was replaced with iPSC medium containing basic fibroblast growth factor (4 ng/ml); thereafter, the medium was changed every other day. Five weeks after viral transduction, colonies were picked and transferred to 12-well plates containing feeder cells. For expansion, cells were dissociated in a 1:2 solution of accutase/PBS for 1 min at room temperature, washed twice with PBS, and scraped off the dish with a cell lifter in iPSC medium. Larger colonies were further broken up by pipetting and transferred to 6-well plates containing feeder cells. After the initial characterization, selected iPSC lines were adapted and maintained in feeder-free conditions. In the absence of feeder cells, iPSC colonies were seeded onto plates coated with Matrigel (BD Biosciences) and cultured in mTeSR1 medium (StemCell Technologies).</ce:para></ce:section><ce:section id="dtbox1sec2" view="all"><ce:section-title>Bisulfite Sequencing</ce:section-title><ce:para id="p0175" view="all">Genomic DNA was isolated from fibroblasts and iPSCs with the DNeasy blood and tissue kit (QIAGEN), and the EpiTect bisulfite kit (QIAGEN) was used for bisulfite treatment. The OCT4 promoter sequence of interest was amplified by PCR with previously described primers (<ce:cross-ref refid="bib14">Freberg et al., 2007</ce:cross-ref>, primer pair 7). The amplified products were cloned with the TOPO cloning kit (Invitrogen, Carlsbad, CA), purified, and sequenced.</ce:para></ce:section><ce:section id="dtbox1sec3" view="all"><ce:section-title>RNA Extraction and qRT-PCR</ce:section-title><ce:para id="p0180" view="all">Total RNA was isolated with RNeasy kits (QIAGEN), and 500 ng of RNA was reverse transcribed to cDNA with TaqMan reverse transcription reagent kits (Applied Biosystems, Foster City, CA) according to the manufacturer's instructions. Quantitative PCR was performed with SYBR Green Master Mix (Applied Biosystems) and forward and reverse primers (10 μM; <ce:cross-ref refid="mmc1">Table S1</ce:cross-ref>) or with TaqMan Gene Expression Master Mix and TaqMan primers (Applied Biosystems). Ct values for each sample and gene were normalized to <ce:italic>GAPDH</ce:italic>. The 2<ce:sup loc="post">-ΔΔCt</ce:sup> method was used to determine the relative expression of each gene. The putative iPSC lines were first analyzed for the four reprogramming factors at passage #8, almost two months after the picking of the colonies. The primers are listed in <ce:cross-ref refid="mmc1">Table S1</ce:cross-ref>. At this stage, the transgene expression was between one to four times higher than the endogenous levels of ESC H9, except for two lines where the KLF4 transgene was twenty times higher than the endogenous levels. These two lines were not used in this study. Thus, our assay allows us to detect transgene expression levels of at least 20-fold above the endogenous ESC H9 levels.</ce:para></ce:section><ce:section id="dtbox1sec4" view="all"><ce:section-title>Immunocytochemistry</ce:section-title><ce:para id="p0185" view="all">Cells were fixed in 4% paraformaldehyde (pH 7.4) for 10 min and permeabilized with 0.2% Triton X-100. After incubation with 3% bovine serum albumin for 30 min, cells were incubated with primary antibodies for 1 hr at room temperature. The primary antibodies used were mouse anti-OCT4 (Santa Cruz Biotechnology, Santa Cruz, CA; 1:100), mouse anti-TRA-1-60 and TRA-1-80 (Millipore; 1:100), goat anti-NANOG (R&amp;D Systems, Minneapolis, MN; 1:100), mouse anti-SSEA4 (Abcam, Cambridge, MA; 1:100), rabbit anti-desmin (Thermo Scientific, Waltham, MA; 1:100), mouse anti-βIII-tubulin (Promega, Madison, WI; 1:200), mouse anti-α-fetoprotein (R&amp;D Systems; 1:200), mouse anti-MAP2 (Sigma, St. Louis, MO; 1:500), rabbit anti-glial fibrillary acidic protein (Dako, Carpinteria, CA; 1:1000), rabbit anti-VGLUT1 (Synaptic Systems, Goettingen, Germany; 1:500), rabbit anti-GABA (Sigma; 1:100), rabbit anti-tyrosine hydroxylase (Millipore, Billerica, MA; 1:500), rabbit anti-TDP43 (Protein Tech Group, Chicago, IL; 1:100). After three washes with PBS, the cells were incubated with Alexa Fluor secondary antibodies (Invitrogen; 1:300) for 1 hr at room temperature followed by counter staining with 1 μg/ml Hoechst or DAPI. Immunostained cells were examined with an Axiovert 200 fluorescence microscope coupled to an Axiocam camera (Zeiss). For neuron experiments, on average 200 cells were analyzed per experimental condition, n = 3 independent cultures.</ce:para></ce:section><ce:section id="dtbox1sec5" view="all"><ce:section-title>Neuronal Differentiation of iPSC Lines</ce:section-title><ce:para id="p0190" view="all">iPSC colonies were detached with accutase (Millipore) and grown as embryoid bodies (EBs) in suspension for 5-6 days in iPSC medium without basic fibroblast growth factor. EBs were allowed to attach and form rosettes. Ten-day-old rosettes were collected and grown in suspension as neurospheres. Neurospheres were dissociated after 3-4 weeks, and the cells were plated on glass coverslips (BD Biosciences) or plates coated with poly-D-lysine (0.1 mg/ml) and laminin (10 μg/m). Neurons were used after 2-4 weeks in culture.</ce:para><ce:para id="p0195" view="all">For spontaneous differentiation, EBs were obtained as described for neural differentiation and grown for 8 days in suspension. EBs were then allowed to adhere to Matrigel-coated glass coverslips and to further differentiate for 8 days in mTeSR1 medium. Cells migrating out of the attached EBs were stained and analyzed by fluorescence microscopy for markers of the three germ layers.</ce:para></ce:section><ce:section id="dtbox1sec6" view="all"><ce:section-title>Karyotyping and Teratoma Formation</ce:section-title><ce:para id="p0200" view="all">Karyotype analysis was performed at Cell Line Genetics (Madison, WI) and Cytogenetic Laboratory, University of Massachusetts Memorial Hospital (Worcester, MA). Teratoma formation was analyzed at Applied StemCell (Sunnyvale, CA). Briefly, iPSCs (1-2 × 10<ce:sup loc="post">6</ce:sup> cells/site) were injected into the kidney capsule of Fox Chase SCID-beige mice. Teratomas formed 7-10 weeks later. Tissues were fixed in 10% formalin, embedded in paraffin, cut into 5-μm serial sections, and stained with hematoxylin/eosin.</ce:para></ce:section><ce:section id="dtbox1sec7" view="all"><ce:section-title>Differentiation of iPSCs into Microglia</ce:section-title><ce:para id="p0205" view="all">iPSCs were differentiated into microglial precursors in vivo with a modified version of a method designed for mouse ESCs (<ce:cross-ref refid="bib21">Napoli et al., 2009</ce:cross-ref>). Briefly, EBs were formed as described for neuronal differentiation, cultured in suspension for 6 days, and allowed to adhere to dishes coated with 0.1% gelatin. Twenty-four hours later, nestin-positive cells were selected by incubation with 5 μg/ml fibronectin (Sigma) and 1X insulin-transferrin-selenite (GIBCO) in Dulbecco's modified Eagle's medium (DMEM)/F12 for 6 days. Cells were expanded in DMEM/F12 containing 1% N2, 1 μg/ml laminin, and 5 ng/ml basic fibroblast growth factor for 6 additional days. Differentiation was induced by removing the growth factor from the medium. Twenty-one days later, precursor cells were dissociated with 0.125% trypsin and seeded on gelatin-coated, 100-mm dishes in DMEM/F12 medium containing 1% N2 and 5% fetal bovine serum. Microglial cells migrating out of the aggregates were collected 14 days later and seeded on gelatin-coated 24-well plates. Experiments were performed 48 hr later.</ce:para></ce:section><ce:section id="dtbox1sec8" view="all"><ce:section-title>Electrophysiology</ce:section-title><ce:para id="p0210" view="all">Electrophysiological recording were performed on 3-4 week-old neurons. The extracellular solution consisted of (in mM) 119 NaCl, 2.5 KCl, 4 CaCl<ce:inf loc="post">2</ce:inf>, 4 MgCl<ce:inf loc="post">2</ce:inf>, 26 NaHCO<ce:inf loc="post">3</ce:inf>, 1 NaH<ce:inf loc="post">2</ce:inf>PO<ce:inf loc="post">4</ce:inf>, and 11 glucose; it was gassed with 5% CO<ce:inf loc="post">2</ce:inf>/95% O<ce:inf loc="post">2</ce:inf> and had a pH of 7.4, unless otherwise noted. The coverslips were mounted on an upright microscope (BX61WI, Olympus), and cells were identified visually by infrared (IR) differential interference contrast video microscopy with an IR-CCD camera (Olympus). Whole-cell recordings were made with a Multiclamp 700B amplifier, a Digidata 1320, and Clampex 9 (Molecular Devices). The patch recording pipettes (3-5 MΩ) were filled with internal solution containing (in mM): 115 potassium methanesulfonate, 20 KCl, 10 HEPES, 2.5 MgCl<ce:inf loc="post">2</ce:inf>, 4 adenosine triphosphate disodium salt, 0.4 guanosine triphosphate trisodium salt, 10 sodium phosphocreatine, and 0.6 EGTA, pH 7.25, with KOH. Membrane potentials were corrected for a liquid junction potential (10 mV) between the extracellular and pipette solutions. All experiments were performed at room temperature (24-25°C). Action potentials were recorded in whole-cell current-clamp mode. Membrane potentials were kept around -55 to 65 mV, and step currents were injected to evoke action potentials. AMPAR-mediated miniature excitatory postsynaptic currents (mEPSCs) were measured with whole-cell voltage-clamp recordings performed with tetrodotoxin (0.002 mM, Ascent Scientific) and picrotoxin (0.1 mM, Sigma) in the extracellular solution. Miniature events were analyzed with Mini Analysis software (Synaptosoft). Events smaller than 5 pA were excluded from the analysis. Data were digitized at 10k Hz with a 2-kHz low-pass filter. Results are reported as mean ± SEM. The statistical significance of differences in mEPSCs was determined by t test; p &lt; 0.05 was considered statistically significant.</ce:para></ce:section><ce:section id="dtbox1sec9" view="all"><ce:section-title>Caspase-3 Activity Assay</ce:section-title><ce:para id="p0215" view="all">Cells were washed once in PBS and lysed with M-PER Reagent (Thermo Scientific) supplemented with protease inhibitor cocktail (Roche Applied Science). After three freeze-thaw cycles, cellular debris was removed by centrifugation at 13,000 rpm for 10 min at 4°C, and the supernatants were assayed for protein concentration with the BioRad reagent assay. To measure caspase-3-like activity, 10 μg of protein was incubated with 15 μM Ac-DEVD-AFC (Caspase-3 Substrate VII, Calbiochem, San Diego, CA) in reaction buffer (25 mM HEPES, 10% sucrose, 0.1% CHAPS, pH 7.5, and 15 mM 1,4 dithiothreitol) for 2 hr at 37°C. AFC fluorescence was detected with excitation at 400 nm and emission at 505 nm in a SpectraMax M3 Microplate Reader (Molecular Devices, Sunnyvale, CA). Caspase-like activity was calculated as the increase above control (DMSO-treated cells).</ce:para></ce:section><ce:section id="dtbox1sec10" view="all"><ce:section-title>Microarray Experiments</ce:section-title><ce:para id="p0220" view="all">Total RNA was extracted from neuronal cultures with standard methods, and then amplified, biotin-labeled, and hybridized on Illumina HT12 version 4 Beadchip Expression microarrays, following the manufacturer's recommendations. Slides were scanned using Illumina BeadStation, and the signal was extracted by using Illumina BeadStudio software. Raw data were analyzed by using Bioconductor packages [Gentleman R, Carey V, Huber W et al. Bioinformatics and Computational Biology Solutions Using R and Bioconductor: Springer, 2005]. Quality assessment was performed analyzing at the inter-array Pearson correlation, and clustering based on top variant genes was used to assess overall data coherence. Contrast analysis of differential expression was performed by using the LIMMA package [Smyth GK, Gentleman R, Carey V et al. Limma: linear models for microarray data. Bioinformatics and Computational Biology Solutions using R and Bioconductor: Springer, 2005:397-420]. After linear model fitting, a Bayesian estimate of differential expression was calculated. Data analysis was aimed at characterizing the gene expression differences between neurons from a sporadic FTD subject and a carrier the PGRN S116X mutation compared to neurons derived from one normal control. Pathway analysis was performed by using the Functional Analysis Annotation tool in the Ingenuity Pathways Analysis software (Ingenuity Systems, <ce:inter-ref xlink:href="http://www.ingenuity.com" xlink:type="simple">http://www.ingenuity.com</ce:inter-ref>).</ce:para></ce:section><ce:section id="dtbox1sec11" view="all"><ce:section-title>Statistical Analysis</ce:section-title><ce:para id="p0225" view="all">Values are expressed as mean ± SEM. The significance of differences among multiple groups was determined with a one-way analysis of variance (ANOVA) followed by a Tukey-Kramer post hoc test (GraphPad Prism version 5.04). Differences were considered significant at p &lt; 0.05.</ce:para></ce:section></ce:sections></ce:textbox-body></ce:textbox></ce:display></ce:para></ce:section></ce:sections><ce:acknowledgment><ce:section-title>Acknowledgments</ce:section-title><ce:para id="p0230" view="all">We thank our patients and their families, whose generosity made this research possible. We also thank S. Ordway for editorial assistance, J.A. Lee for help at the early stage of this project, and J. Miller and members of the Gao laboratory for discussions. This work was initiated with a grant from the California Institute for Regenerative Medicine (RL1-00650 to F.B.G. and R.V.F., Jr.) when F.B.G. was at the J. David Gladstone Institutes and supported by startup funds from the University of Massachusetts Medical School (F.B.G. and K.F.). This work was also partially supported by the National Institutes of Health (NS057553 to F.B.G., and AG019724 and AG023501 to B.L.M.) and the Consortium for FTD Research (F.B.G. and D.H.G.).</ce:para></ce:acknowledgment><ce:appendices view="all"><ce:section id="app1" view="all"><ce:section-title>Accession Numbers</ce:section-title><ce:para id="p0235" view="all">Microarray data are available at the NCBI Gene Expression Omnibus database under the series accession number <ce:inter-ref xlink:href="ncbi-geo:GSE40378" xlink:type="simple">GSE40378</ce:inter-ref>.</ce:para></ce:section><ce:section id="app2" view="compact-standard"><ce:section-title>Supplemental Information</ce:section-title><ce:para id="p0240" view="all">Supplemental Information includes Extended Experimental Procedures, four figures, and one table and can be found with this article online at <ce:inter-ref xlink:href="doi:10.1016/j.celrep.2012.09.007" xlink:type="simple">http://dx.doi.org/10.1016/j.celrep.2012.09.007</ce:inter-ref>.</ce:para></ce:section><ce:section id="app3" view="compact-standard"><ce:section-title>Licensing Information</ce:section-title><ce:para id="p0245" view="all">This is an open-access article distributed under the terms of the Creative Commons Attribution 3.0 Unported License (CC-BY; <ce:inter-ref xlink:href="http://creativecommons.org/licenses/by/3.0/legalcode" xlink:type="simple">http://creativecommons.org/licenses/by/3.0/legalcode</ce:inter-ref>).</ce:para></ce:section><ce:section id="app4" view="extended"><ce:section-title>Supplemental Information</ce:section-title><ce:para id="p0250" view="all"><ce:display><ce:e-component id="mmc1"><ce:label>Table S1. Primer for qPCR and PCR Reactions, Related to Experimental Procedures</ce:label><ce:link locator="mmc1"/></ce:e-component></ce:display><ce:display><ce:e-component id="mmc2" role="article-plus"><ce:label>Document S1. Article plus Supplemental Information</ce:label><ce:link locator="mmc2"/></ce:e-component></ce:display></ce:para></ce:section></ce:appendices></body><tail view="all"><ce:bibliography id="cebib0010" view="all"><ce:section-title>References</ce:section-title><ce:bibliography-sec id="cebibsec0010"><ce:bib-reference id="bib1"><ce:label>Ahmed et al., 2010</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>Z.</ce:given-name><ce:surname>Ahmed</ce:surname></sb:author><sb:author><ce:given-name>H.</ce:given-name><ce:surname>Sheng</ce:surname></sb:author><sb:author><ce:given-name>Y.F.</ce:given-name><ce:surname>Xu</ce:surname></sb:author><sb:author><ce:given-name>W.L.</ce:given-name><ce:surname>Lin</ce:surname></sb:author><sb:author><ce:given-name>A.E.</ce:given-name><ce:surname>Innes</ce:surname></sb:author><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Gass</ce:surname></sb:author><sb:author><ce:given-name>X.</ce:given-name><ce:surname>Yu</ce:surname></sb:author><sb:author><ce:given-name>C.A.</ce:given-name><ce:surname>Wuertzer</ce:surname></sb:author><sb:author><ce:given-name>H.</ce:given-name><ce:surname>Hou</ce:surname></sb:author><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Chiba</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>Accelerated lipofuscinosis and ubiquitination in granulin knockout mice suggest a role for progranulin in successful aging</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Am. J. Pathol.</sb:maintitle></sb:title><sb:volume-nr>177</sb:volume-nr></sb:series><sb:date>2010</sb:date></sb:issue><sb:pages><sb:first-page>311</sb:first-page><sb:last-page>324</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib2"><ce:label>Baker et al., 2006</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Baker</ce:surname></sb:author><sb:author><ce:given-name>I.R.</ce:given-name><ce:surname>Mackenzie</ce:surname></sb:author><sb:author><ce:given-name>S.M.</ce:given-name><ce:surname>Pickering-Brown</ce:surname></sb:author><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Gass</ce:surname></sb:author><sb:author><ce:given-name>R.</ce:given-name><ce:surname>Rademakers</ce:surname></sb:author><sb:author><ce:given-name>C.</ce:given-name><ce:surname>Lindholm</ce:surname></sb:author><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Snowden</ce:surname></sb:author><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Adamson</ce:surname></sb:author><sb:author><ce:given-name>A.D.</ce:given-name><ce:surname>Sadovnick</ce:surname></sb:author><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Rollinson</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Nature</sb:maintitle></sb:title><sb:volume-nr>442</sb:volume-nr></sb:series><sb:date>2006</sb:date></sb:issue><sb:pages><sb:first-page>916</sb:first-page><sb:last-page>919</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib3"><ce:label>Boxer and Miller, 2005</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>A.L.</ce:given-name><ce:surname>Boxer</ce:surname></sb:author><sb:author><ce:given-name>B.L.</ce:given-name><ce:surname>Miller</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Clinical features of frontotemporal dementia</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Alzheimer Dis. Assoc. Disord.</sb:maintitle></sb:title><sb:volume-nr>19</sb:volume-nr></sb:series><sb:issue-nr>Suppl 1</sb:issue-nr><sb:date>2005</sb:date></sb:issue><sb:pages><sb:first-page>S3</sb:first-page><sb:last-page>S6</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib4"><ce:label>Chen-Plotkin et al., 2008</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>A.S.</ce:given-name><ce:surname>Chen-Plotkin</ce:surname></sb:author><sb:author><ce:given-name>F.</ce:given-name><ce:surname>Geser</ce:surname></sb:author><sb:author><ce:given-name>J.B.</ce:given-name><ce:surname>Plotkin</ce:surname></sb:author><sb:author><ce:given-name>C.M.</ce:given-name><ce:surname>Clark</ce:surname></sb:author><sb:author><ce:given-name>L.K.</ce:given-name><ce:surname>Kwong</ce:surname></sb:author><sb:author><ce:given-name>W.</ce:given-name><ce:surname>Yuan</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Grossman</ce:surname></sb:author><sb:author><ce:given-name>V.M.</ce:given-name><ce:surname>Van Deerlin</ce:surname></sb:author><sb:author><ce:given-name>J.Q.</ce:given-name><ce:surname>Trojanowski</ce:surname></sb:author><sb:author><ce:given-name>V.M.</ce:given-name><ce:surname>Lee</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Variations in the progranulin gene affect global gene expression in frontotemporal lobar degeneration</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Hum. Mol. Genet.</sb:maintitle></sb:title><sb:volume-nr>17</sb:volume-nr></sb:series><sb:date>2008</sb:date></sb:issue><sb:pages><sb:first-page>1349</sb:first-page><sb:last-page>1362</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib5"><ce:label>Chen-Plotkin et al., 2010</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>A.S.</ce:given-name><ce:surname>Chen-Plotkin</ce:surname></sb:author><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Xiao</ce:surname></sb:author><sb:author><ce:given-name>F.</ce:given-name><ce:surname>Geser</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Martinez-Lage</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Grossman</ce:surname></sb:author><sb:author><ce:given-name>T.</ce:given-name><ce:surname>Unger</ce:surname></sb:author><sb:author><ce:given-name>E.M.</ce:given-name><ce:surname>Wood</ce:surname></sb:author><sb:author><ce:given-name>V.M.</ce:given-name><ce:surname>Van Deerlin</ce:surname></sb:author><sb:author><ce:given-name>J.Q.</ce:given-name><ce:surname>Trojanowski</ce:surname></sb:author><sb:author><ce:given-name>V.M.</ce:given-name><ce:surname>Lee</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Brain progranulin expression in GRN-associated frontotemporal lobar degeneration</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Acta Neuropathol.</sb:maintitle></sb:title><sb:volume-nr>119</sb:volume-nr></sb:series><sb:date>2010</sb:date></sb:issue><sb:pages><sb:first-page>111</sb:first-page><sb:last-page>122</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib6"><ce:label>Colla et al., 2012</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>E.</ce:given-name><ce:surname>Colla</ce:surname></sb:author><sb:author><ce:given-name>P.</ce:given-name><ce:surname>Coune</ce:surname></sb:author><sb:author><ce:given-name>Y.</ce:given-name><ce:surname>Liu</ce:surname></sb:author><sb:author><ce:given-name>O.</ce:given-name><ce:surname>Pletnikova</ce:surname></sb:author><sb:author><ce:given-name>J.C.</ce:given-name><ce:surname>Troncoso</ce:surname></sb:author><sb:author><ce:given-name>T.</ce:given-name><ce:surname>Iwatsubo</ce:surname></sb:author><sb:author><ce:given-name>B.L.</ce:given-name><ce:surname>Schneider</ce:surname></sb:author><sb:author><ce:given-name>M.K.</ce:given-name><ce:surname>Lee</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Endoplasmic reticulum stress is important for the manifestations of α-synucleinopathy in vivo</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Neurosci.</sb:maintitle></sb:title><sb:volume-nr>32</sb:volume-nr></sb:series><sb:date>2012</sb:date></sb:issue><sb:pages><sb:first-page>3306</sb:first-page><sb:last-page>3320</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib7"><ce:label>Coppola et al., 2008</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>G.</ce:given-name><ce:surname>Coppola</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Karydas</ce:surname></sb:author><sb:author><ce:given-name>R.</ce:given-name><ce:surname>Rademakers</ce:surname></sb:author><sb:author><ce:given-name>Q.</ce:given-name><ce:surname>Wang</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Baker</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Hutton</ce:surname></sb:author><sb:author><ce:given-name>B.L.</ce:given-name><ce:surname>Miller</ce:surname></sb:author><sb:author><ce:given-name>D.H.</ce:given-name><ce:surname>Geschwind</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Gene expression study on peripheral blood identifies progranulin mutations</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Ann. Neurol.</sb:maintitle></sb:title><sb:volume-nr>64</sb:volume-nr></sb:series><sb:date>2008</sb:date></sb:issue><sb:pages><sb:first-page>92</sb:first-page><sb:last-page>96</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib8"><ce:label>Cruts et al., 2006</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Cruts</ce:surname></sb:author><sb:author><ce:given-name>I.</ce:given-name><ce:surname>Gijselinck</ce:surname></sb:author><sb:author><ce:given-name>J.</ce:given-name><ce:surname>van der Zee</ce:surname></sb:author><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Engelborghs</ce:surname></sb:author><sb:author><ce:given-name>H.</ce:given-name><ce:surname>Wils</ce:surname></sb:author><sb:author><ce:given-name>D.</ce:given-name><ce:surname>Pirici</ce:surname></sb:author><sb:author><ce:given-name>R.</ce:given-name><ce:surname>Rademakers</ce:surname></sb:author><sb:author><ce:given-name>R.</ce:given-name><ce:surname>Vandenberghe</ce:surname></sb:author><sb:author><ce:given-name>B.</ce:given-name><ce:surname>Dermaut</ce:surname></sb:author><sb:author><ce:given-name>J.J.</ce:given-name><ce:surname>Martin</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Nature</sb:maintitle></sb:title><sb:volume-nr>442</sb:volume-nr></sb:series><sb:date>2006</sb:date></sb:issue><sb:pages><sb:first-page>920</sb:first-page><sb:last-page>924</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib9"><ce:label>DeJesus-Hernandez et al., 2011</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>M.</ce:given-name><ce:surname>DeJesus-Hernandez</ce:surname></sb:author><sb:author><ce:given-name>I.R.</ce:given-name><ce:surname>Mackenzie</ce:surname></sb:author><sb:author><ce:given-name>B.F.</ce:given-name><ce:surname>Boeve</ce:surname></sb:author><sb:author><ce:given-name>A.L.</ce:given-name><ce:surname>Boxer</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Baker</ce:surname></sb:author><sb:author><ce:given-name>N.J.</ce:given-name><ce:surname>Rutherford</ce:surname></sb:author><sb:author><ce:given-name>A.M.</ce:given-name><ce:surname>Nicholson</ce:surname></sb:author><sb:author><ce:given-name>N.A.</ce:given-name><ce:surname>Finch</ce:surname></sb:author><sb:author><ce:given-name>H.</ce:given-name><ce:surname>Flynn</ce:surname></sb:author><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Adamson</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Neuron</sb:maintitle></sb:title><sb:volume-nr>72</sb:volume-nr></sb:series><sb:date>2011</sb:date></sb:issue><sb:pages><sb:first-page>245</sb:first-page><sb:last-page>256</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib10"><ce:label>Delaloy et al., 2010</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>C.</ce:given-name><ce:surname>Delaloy</ce:surname></sb:author><sb:author><ce:given-name>L.</ce:given-name><ce:surname>Liu</ce:surname></sb:author><sb:author><ce:given-name>J.-A.</ce:given-name><ce:surname>Lee</ce:surname></sb:author><sb:author><ce:given-name>H.</ce:given-name><ce:surname>Su</ce:surname></sb:author><sb:author><ce:given-name>F.</ce:given-name><ce:surname>Shen</ce:surname></sb:author><sb:author><ce:given-name>G.Y.</ce:given-name><ce:surname>Yang</ce:surname></sb:author><sb:author><ce:given-name>W.L.</ce:given-name><ce:surname>Young</ce:surname></sb:author><sb:author><ce:given-name>K.N.</ce:given-name><ce:surname>Ivey</ce:surname></sb:author><sb:author><ce:given-name>F.B.</ce:given-name><ce:surname>Gao</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>MicroRNA-9 coordinates proliferation and migration of human embryonic stem cell-derived neural progenitors</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Cell Stem Cell</sb:maintitle></sb:title><sb:volume-nr>6</sb:volume-nr></sb:series><sb:date>2010</sb:date></sb:issue><sb:pages><sb:first-page>323</sb:first-page><sb:last-page>335</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib11"><ce:label>Dimos et al., 2008</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>J.T.</ce:given-name><ce:surname>Dimos</ce:surname></sb:author><sb:author><ce:given-name>K.T.</ce:given-name><ce:surname>Rodolfa</ce:surname></sb:author><sb:author><ce:given-name>K.K.</ce:given-name><ce:surname>Niakan</ce:surname></sb:author><sb:author><ce:given-name>L.M.</ce:given-name><ce:surname>Weisenthal</ce:surname></sb:author><sb:author><ce:given-name>H.</ce:given-name><ce:surname>Mitsumoto</ce:surname></sb:author><sb:author><ce:given-name>W.</ce:given-name><ce:surname>Chung</ce:surname></sb:author><sb:author><ce:given-name>G.F.</ce:given-name><ce:surname>Croft</ce:surname></sb:author><sb:author><ce:given-name>G.</ce:given-name><ce:surname>Saphier</ce:surname></sb:author><sb:author><ce:given-name>R.</ce:given-name><ce:surname>Leibel</ce:surname></sb:author><sb:author><ce:given-name>R.</ce:given-name><ce:surname>Goland</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Science</sb:maintitle></sb:title><sb:volume-nr>321</sb:volume-nr></sb:series><sb:date>2008</sb:date></sb:issue><sb:pages><sb:first-page>1218</sb:first-page><sb:last-page>1221</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib12"><ce:label>Ebert et al., 2009</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>A.D.</ce:given-name><ce:surname>Ebert</ce:surname></sb:author><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Yu</ce:surname></sb:author><sb:author><ce:given-name>F.F.</ce:given-name><ce:surname>Rose</ce:surname><ce:suffix>Jr.</ce:suffix></sb:author><sb:author><ce:given-name>V.B.</ce:given-name><ce:surname>Mattis</ce:surname></sb:author><sb:author><ce:given-name>C.L.</ce:given-name><ce:surname>Lorson</ce:surname></sb:author><sb:author><ce:given-name>J.A.</ce:given-name><ce:surname>Thomson</ce:surname></sb:author><sb:author><ce:given-name>C.N.</ce:given-name><ce:surname>Svendsen</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Induced pluripotent stem cells from a spinal muscular atrophy patient</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Nature</sb:maintitle></sb:title><sb:volume-nr>457</sb:volume-nr></sb:series><sb:date>2009</sb:date></sb:issue><sb:pages><sb:first-page>277</sb:first-page><sb:last-page>280</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib13"><ce:label>Fenton and Gout, 2011</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>T.R.</ce:given-name><ce:surname>Fenton</ce:surname></sb:author><sb:author><ce:given-name>I.T.</ce:given-name><ce:surname>Gout</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Functions and regulation of the 70kDa ribosomal S6 kinases</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Int. J. Biochem. Cell Biol.</sb:maintitle></sb:title><sb:volume-nr>43</sb:volume-nr></sb:series><sb:date>2011</sb:date></sb:issue><sb:pages><sb:first-page>47</sb:first-page><sb:last-page>59</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib14"><ce:label>Freberg et al., 2007</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>C.T.</ce:given-name><ce:surname>Freberg</ce:surname></sb:author><sb:author><ce:given-name>J.A.</ce:given-name><ce:surname>Dahl</ce:surname></sb:author><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Timoskainen</ce:surname></sb:author><sb:author><ce:given-name>P.</ce:given-name><ce:surname>Collas</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Epigenetic reprogramming of OCT4 and NANOG regulatory regions by embryonal carcinoma cell extract</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Mol. Biol. Cell</sb:maintitle></sb:title><sb:volume-nr>18</sb:volume-nr></sb:series><sb:date>2007</sb:date></sb:issue><sb:pages><sb:first-page>1543</sb:first-page><sb:last-page>1553</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib15"><ce:label>Finch et al., 2009</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>N.</ce:given-name><ce:surname>Finch</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Baker</ce:surname></sb:author><sb:author><ce:given-name>R.</ce:given-name><ce:surname>Crook</ce:surname></sb:author><sb:author><ce:given-name>K.</ce:given-name><ce:surname>Swanson</ce:surname></sb:author><sb:author><ce:given-name>K.</ce:given-name><ce:surname>Kuntz</ce:surname></sb:author><sb:author><ce:given-name>R.</ce:given-name><ce:surname>Surtees</ce:surname></sb:author><sb:author><ce:given-name>G.</ce:given-name><ce:surname>Bisceglio</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Rovelet-Lecrux</ce:surname></sb:author><sb:author><ce:given-name>B.</ce:given-name><ce:surname>Boeve</ce:surname></sb:author><sb:author><ce:given-name>R.C.</ce:given-name><ce:surname>Petersen</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>Plasma progranulin levels predict progranulin mutation status in frontotemporal dementia patients and asymptomatic family members</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Brain</sb:maintitle></sb:title><sb:volume-nr>132</sb:volume-nr></sb:series><sb:date>2009</sb:date></sb:issue><sb:pages><sb:first-page>583</sb:first-page><sb:last-page>591</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib16"><ce:label>Ghoshal et al., 2012</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>N.</ce:given-name><ce:surname>Ghoshal</ce:surname></sb:author><sb:author><ce:given-name>J.T.</ce:given-name><ce:surname>Dearborn</ce:surname></sb:author><sb:author><ce:given-name>D.F.</ce:given-name><ce:surname>Wozniak</ce:surname></sb:author><sb:author><ce:given-name>N.J.</ce:given-name><ce:surname>Cairns</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Core features of frontotemporal dementia recapitulated in progranulin knockout mice</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Neurobiol. Dis.</sb:maintitle></sb:title><sb:volume-nr>45</sb:volume-nr></sb:series><sb:date>2012</sb:date></sb:issue><sb:pages><sb:first-page>395</sb:first-page><sb:last-page>408</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib17"><ce:label>He and Bateman, 2003</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>Z.</ce:given-name><ce:surname>He</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Bateman</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Progranulin (granulin-epithelin precursor, PC-cell-derived growth factor, acrogranin) mediates tissue repair and tumorigenesis</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Mol. Med.</sb:maintitle></sb:title><sb:volume-nr>81</sb:volume-nr></sb:series><sb:date>2003</sb:date></sb:issue><sb:pages><sb:first-page>600</sb:first-page><sb:last-page>612</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib18"><ce:label>Hoozemans et al., 2009</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>J.J.</ce:given-name><ce:surname>Hoozemans</ce:surname></sb:author><sb:author><ce:given-name>E.S.</ce:given-name><ce:surname>van Haastert</ce:surname></sb:author><sb:author><ce:given-name>D.A.</ce:given-name><ce:surname>Nijholt</ce:surname></sb:author><sb:author><ce:given-name>A.J.</ce:given-name><ce:surname>Rozemuller</ce:surname></sb:author><sb:author><ce:given-name>P.</ce:given-name><ce:surname>Eikelenboom</ce:surname></sb:author><sb:author><ce:given-name>W.</ce:given-name><ce:surname>Scheper</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>The unfolded protein response is activated in pretangle neurons in Alzheimer's disease hippocampus</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Am. J. Pathol.</sb:maintitle></sb:title><sb:volume-nr>174</sb:volume-nr></sb:series><sb:date>2009</sb:date></sb:issue><sb:pages><sb:first-page>1241</sb:first-page><sb:last-page>1251</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib19"><ce:label>Israel et al., 2012</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>M.A.</ce:given-name><ce:surname>Israel</ce:surname></sb:author><sb:author><ce:given-name>S.H.</ce:given-name><ce:surname>Yuan</ce:surname></sb:author><sb:author><ce:given-name>C.</ce:given-name><ce:surname>Bardy</ce:surname></sb:author><sb:author><ce:given-name>S.M.</ce:given-name><ce:surname>Reyna</ce:surname></sb:author><sb:author><ce:given-name>Y.</ce:given-name><ce:surname>Mu</ce:surname></sb:author><sb:author><ce:given-name>C.</ce:given-name><ce:surname>Herrera</ce:surname></sb:author><sb:author><ce:given-name>M.P.</ce:given-name><ce:surname>Hefferan</ce:surname></sb:author><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Van Gorp</ce:surname></sb:author><sb:author><ce:given-name>K.L.</ce:given-name><ce:surname>Nazor</ce:surname></sb:author><sb:author><ce:given-name>F.S.</ce:given-name><ce:surname>Boscolo</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Nature</sb:maintitle></sb:title><sb:volume-nr>482</sb:volume-nr></sb:series><sb:date>2012</sb:date></sb:issue><sb:pages><sb:first-page>216</sb:first-page><sb:last-page>220</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib20"><ce:label>Matus et al., 2011</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Matus</ce:surname></sb:author><sb:author><ce:given-name>L.H.</ce:given-name><ce:surname>Glimcher</ce:surname></sb:author><sb:author><ce:given-name>C.</ce:given-name><ce:surname>Hetz</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Protein folding stress in neurodegenerative diseases: a glimpse into the ER</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Curr. Opin. Cell Biol.</sb:maintitle></sb:title><sb:volume-nr>23</sb:volume-nr></sb:series><sb:date>2011</sb:date></sb:issue><sb:pages><sb:first-page>239</sb:first-page><sb:last-page>252</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib21"><ce:label>Napoli et al., 2009</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>I.</ce:given-name><ce:surname>Napoli</ce:surname></sb:author><sb:author><ce:given-name>K.</ce:given-name><ce:surname>Kierdorf</ce:surname></sb:author><sb:author><ce:given-name>H.</ce:given-name><ce:surname>Neumann</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Microglial precursors derived from mouse embryonic stem cells</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Glia</sb:maintitle></sb:title><sb:volume-nr>57</sb:volume-nr></sb:series><sb:date>2009</sb:date></sb:issue><sb:pages><sb:first-page>1660</sb:first-page><sb:last-page>1671</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib22"><ce:label>Neumann et al., 2006</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Neumann</ce:surname></sb:author><sb:author><ce:given-name>D.M.</ce:given-name><ce:surname>Sampathu</ce:surname></sb:author><sb:author><ce:given-name>L.K.</ce:given-name><ce:surname>Kwong</ce:surname></sb:author><sb:author><ce:given-name>A.C.</ce:given-name><ce:surname>Truax</ce:surname></sb:author><sb:author><ce:given-name>M.C.</ce:given-name><ce:surname>Micsenyi</ce:surname></sb:author><sb:author><ce:given-name>T.T.</ce:given-name><ce:surname>Chou</ce:surname></sb:author><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Bruce</ce:surname></sb:author><sb:author><ce:given-name>T.</ce:given-name><ce:surname>Schuck</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Grossman</ce:surname></sb:author><sb:author><ce:given-name>C.M.</ce:given-name><ce:surname>Clark</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Science</sb:maintitle></sb:title><sb:volume-nr>314</sb:volume-nr></sb:series><sb:date>2006</sb:date></sb:issue><sb:pages><sb:first-page>130</sb:first-page><sb:last-page>133</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib23"><ce:label>Nguyen et al., 2011</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>H.N.</ce:given-name><ce:surname>Nguyen</ce:surname></sb:author><sb:author><ce:given-name>B.</ce:given-name><ce:surname>Byers</ce:surname></sb:author><sb:author><ce:given-name>B.</ce:given-name><ce:surname>Cord</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Shcheglovitov</ce:surname></sb:author><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Byrne</ce:surname></sb:author><sb:author><ce:given-name>P.</ce:given-name><ce:surname>Gujar</ce:surname></sb:author><sb:author><ce:given-name>K.</ce:given-name><ce:surname>Kee</ce:surname></sb:author><sb:author><ce:given-name>B.</ce:given-name><ce:surname>Schüle</ce:surname></sb:author><sb:author><ce:given-name>R.E.</ce:given-name><ce:surname>Dolmetsch</ce:surname></sb:author><sb:author><ce:given-name>W.</ce:given-name><ce:surname>Langston</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Cell Stem Cell</sb:maintitle></sb:title><sb:volume-nr>8</sb:volume-nr></sb:series><sb:date>2011</sb:date></sb:issue><sb:pages><sb:first-page>267</sb:first-page><sb:last-page>280</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib24"><ce:label>Nijholt et al., 2012</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>D.A.</ce:given-name><ce:surname>Nijholt</ce:surname></sb:author><sb:author><ce:given-name>E.S.</ce:given-name><ce:surname>van Haastert</ce:surname></sb:author><sb:author><ce:given-name>A.J.</ce:given-name><ce:surname>Rozemuller</ce:surname></sb:author><sb:author><ce:given-name>W.</ce:given-name><ce:surname>Scheper</ce:surname></sb:author><sb:author><ce:given-name>J.J.</ce:given-name><ce:surname>Hoozemans</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>The unfolded protein response is associated with early tau pathology in the hippocampus of tauopathies</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Pathol.</sb:maintitle></sb:title><sb:volume-nr>226</sb:volume-nr></sb:series><sb:date>2012</sb:date></sb:issue><sb:pages><sb:first-page>693</sb:first-page><sb:last-page>702</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib25"><ce:label>Petkau et al., 2012</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>T.L.</ce:given-name><ce:surname>Petkau</ce:surname></sb:author><sb:author><ce:given-name>S.J.</ce:given-name><ce:surname>Neal</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Milnerwood</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Mew</ce:surname></sb:author><sb:author><ce:given-name>A.M.</ce:given-name><ce:surname>Hill</ce:surname></sb:author><sb:author><ce:given-name>P.</ce:given-name><ce:surname>Orban</ce:surname></sb:author><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Gregg</ce:surname></sb:author><sb:author><ce:given-name>G.</ce:given-name><ce:surname>Lu</ce:surname></sb:author><sb:author><ce:given-name>H.H.</ce:given-name><ce:surname>Feldman</ce:surname></sb:author><sb:author><ce:given-name>I.R.</ce:given-name><ce:surname>Mackenzie</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>Synaptic dysfunction in progranulin-deficient mice</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Neurobiol. Dis.</sb:maintitle></sb:title><sb:volume-nr>45</sb:volume-nr></sb:series><sb:date>2012</sb:date></sb:issue><sb:pages><sb:first-page>711</sb:first-page><sb:last-page>722</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib26"><ce:label>Rosen et al., 2011</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>E.Y.</ce:given-name><ce:surname>Rosen</ce:surname></sb:author><sb:author><ce:given-name>E.M.</ce:given-name><ce:surname>Wexler</ce:surname></sb:author><sb:author><ce:given-name>R.</ce:given-name><ce:surname>Versano</ce:surname></sb:author><sb:author><ce:given-name>G.</ce:given-name><ce:surname>Coppola</ce:surname></sb:author><sb:author><ce:given-name>F.</ce:given-name><ce:surname>Gao</ce:surname></sb:author><sb:author><ce:given-name>K.D.</ce:given-name><ce:surname>Winden</ce:surname></sb:author><sb:author><ce:given-name>M.C.</ce:given-name><ce:surname>Oldham</ce:surname></sb:author><sb:author><ce:given-name>L.H.</ce:given-name><ce:surname>Martens</ce:surname></sb:author><sb:author><ce:given-name>P.</ce:given-name><ce:surname>Zhou</ce:surname></sb:author><sb:author><ce:given-name>R.V.</ce:given-name><ce:surname>Farese</ce:surname><ce:suffix>Jr.</ce:suffix></sb:author><sb:author><ce:given-name>D.H.</ce:given-name><ce:surname>Geschwind</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Functional genomic analyses identify pathways dysregulated by progranulin deficiency, implicating Wnt signaling</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Neuron</sb:maintitle></sb:title><sb:volume-nr>71</sb:volume-nr></sb:series><sb:date>2011</sb:date></sb:issue><sb:pages><sb:first-page>1030</sb:first-page><sb:last-page>1042</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib27"><ce:label>Ryan et al., 2009</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>C.L.</ce:given-name><ce:surname>Ryan</ce:surname></sb:author><sb:author><ce:given-name>D.C.</ce:given-name><ce:surname>Baranowski</ce:surname></sb:author><sb:author><ce:given-name>B.P.</ce:given-name><ce:surname>Chitramuthu</ce:surname></sb:author><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Malik</ce:surname></sb:author><sb:author><ce:given-name>Z.</ce:given-name><ce:surname>Li</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Cao</ce:surname></sb:author><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Minotti</ce:surname></sb:author><sb:author><ce:given-name>H.D.</ce:given-name><ce:surname>Durham</ce:surname></sb:author><sb:author><ce:given-name>D.G.</ce:given-name><ce:surname>Kay</ce:surname></sb:author><sb:author><ce:given-name>C.A.</ce:given-name><ce:surname>Shaw</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>Progranulin is expressed within motor neurons and promotes neuronal cell survival</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>BMC Neurosci.</sb:maintitle></sb:title><sb:volume-nr>10</sb:volume-nr></sb:series><sb:date>2009</sb:date></sb:issue><sb:pages><sb:first-page>130</sb:first-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib28"><ce:label>Renton et al., 2011</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>A.E.</ce:given-name><ce:surname>Renton</ce:surname></sb:author><sb:author><ce:given-name>E.</ce:given-name><ce:surname>Majounie</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Waite</ce:surname></sb:author><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Simón-Sánchez</ce:surname></sb:author><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Rollinson</ce:surname></sb:author><sb:author><ce:given-name>J.R.</ce:given-name><ce:surname>Gibbs</ce:surname></sb:author><sb:author><ce:given-name>J.C.</ce:given-name><ce:surname>Schymick</ce:surname></sb:author><sb:author><ce:given-name>H.</ce:given-name><ce:surname>Laaksovirta</ce:surname></sb:author><sb:author><ce:given-name>J.C.</ce:given-name><ce:surname>van Swieten</ce:surname></sb:author><sb:author><ce:given-name>L.</ce:given-name><ce:surname>Myllykangas</ce:surname></sb:author><sb:et-al/><sb:collaboration>ITALSGEN Consortium</sb:collaboration></sb:authors><sb:title><sb:maintitle>A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Neuron</sb:maintitle></sb:title><sb:volume-nr>72</sb:volume-nr></sb:series><sb:date>2011</sb:date></sb:issue><sb:pages><sb:first-page>257</sb:first-page><sb:last-page>268</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib29"><ce:label>Schon and Przedborski, 2011</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>E.A.</ce:given-name><ce:surname>Schon</ce:surname></sb:author><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Przedborski</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Mitochondria: the next (neurode)generation</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Neuron</sb:maintitle></sb:title><sb:volume-nr>70</sb:volume-nr></sb:series><sb:date>2011</sb:date></sb:issue><sb:pages><sb:first-page>1033</sb:first-page><sb:last-page>1053</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib30"><ce:label>Skibinski et al., 2005</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>G.</ce:given-name><ce:surname>Skibinski</ce:surname></sb:author><sb:author><ce:given-name>N.J.</ce:given-name><ce:surname>Parkinson</ce:surname></sb:author><sb:author><ce:given-name>J.M.</ce:given-name><ce:surname>Brown</ce:surname></sb:author><sb:author><ce:given-name>L.</ce:given-name><ce:surname>Chakrabarti</ce:surname></sb:author><sb:author><ce:given-name>S.L.</ce:given-name><ce:surname>Lloyd</ce:surname></sb:author><sb:author><ce:given-name>H.</ce:given-name><ce:surname>Hummerich</ce:surname></sb:author><sb:author><ce:given-name>J.E.</ce:given-name><ce:surname>Nielsen</ce:surname></sb:author><sb:author><ce:given-name>J.R.</ce:given-name><ce:surname>Hodges</ce:surname></sb:author><sb:author><ce:given-name>M.G.</ce:given-name><ce:surname>Spillantini</ce:surname></sb:author><sb:author><ce:given-name>T.</ce:given-name><ce:surname>Thusgaard</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>Mutations in the endosomal ESCRTIII-complex subunit CHMP2B in frontotemporal dementia</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Nat. Genet.</sb:maintitle></sb:title><sb:volume-nr>37</sb:volume-nr></sb:series><sb:date>2005</sb:date></sb:issue><sb:pages><sb:first-page>806</sb:first-page><sb:last-page>808</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib31"><ce:label>Soldner et al., 2009</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>F.</ce:given-name><ce:surname>Soldner</ce:surname></sb:author><sb:author><ce:given-name>D.</ce:given-name><ce:surname>Hockemeyer</ce:surname></sb:author><sb:author><ce:given-name>C.</ce:given-name><ce:surname>Beard</ce:surname></sb:author><sb:author><ce:given-name>Q.</ce:given-name><ce:surname>Gao</ce:surname></sb:author><sb:author><ce:given-name>G.W.</ce:given-name><ce:surname>Bell</ce:surname></sb:author><sb:author><ce:given-name>E.G.</ce:given-name><ce:surname>Cook</ce:surname></sb:author><sb:author><ce:given-name>G.</ce:given-name><ce:surname>Hargus</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Blak</ce:surname></sb:author><sb:author><ce:given-name>O.</ce:given-name><ce:surname>Cooper</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Mitalipova</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Cell</sb:maintitle></sb:title><sb:volume-nr>136</sb:volume-nr></sb:series><sb:date>2009</sb:date></sb:issue><sb:pages><sb:first-page>964</sb:first-page><sb:last-page>977</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib32"><ce:label>Tapia et al., 2011</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>L.</ce:given-name><ce:surname>Tapia</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Milnerwood</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Guo</ce:surname></sb:author><sb:author><ce:given-name>F.</ce:given-name><ce:surname>Mills</ce:surname></sb:author><sb:author><ce:given-name>E.</ce:given-name><ce:surname>Yoshida</ce:surname></sb:author><sb:author><ce:given-name>C.</ce:given-name><ce:surname>Vasuta</ce:surname></sb:author><sb:author><ce:given-name>I.R.</ce:given-name><ce:surname>Mackenzie</ce:surname></sb:author><sb:author><ce:given-name>L.</ce:given-name><ce:surname>Raymond</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Cynader</ce:surname></sb:author><sb:author><ce:given-name>W.</ce:given-name><ce:surname>Jia</ce:surname></sb:author><sb:author><ce:given-name>S.X.</ce:given-name><ce:surname>Bamji</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Progranulin deficiency decreases gross neural connectivity but enhances transmission at individual synapses</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Neurosci.</sb:maintitle></sb:title><sb:volume-nr>31</sb:volume-nr></sb:series><sb:date>2011</sb:date></sb:issue><sb:pages><sb:first-page>11126</sb:first-page><sb:last-page>11132</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib33"><ce:label>Takahashi et al., 2007</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>K.</ce:given-name><ce:surname>Takahashi</ce:surname></sb:author><sb:author><ce:given-name>K.</ce:given-name><ce:surname>Tanabe</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Ohnuki</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Narita</ce:surname></sb:author><sb:author><ce:given-name>T.</ce:given-name><ce:surname>Ichisaka</ce:surname></sb:author><sb:author><ce:given-name>K.</ce:given-name><ce:surname>Tomoda</ce:surname></sb:author><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Yamanaka</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Induction of pluripotent stem cells from adult human fibroblasts by defined factors</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Cell</sb:maintitle></sb:title><sb:volume-nr>131</sb:volume-nr></sb:series><sb:date>2007</sb:date></sb:issue><sb:pages><sb:first-page>861</sb:first-page><sb:last-page>872</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib34"><ce:label>Van Damme et al., 2008</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>P.</ce:given-name><ce:surname>Van Damme</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Van Hoecke</ce:surname></sb:author><sb:author><ce:given-name>D.</ce:given-name><ce:surname>Lambrechts</ce:surname></sb:author><sb:author><ce:given-name>P.</ce:given-name><ce:surname>Vanacker</ce:surname></sb:author><sb:author><ce:given-name>E.</ce:given-name><ce:surname>Bogaert</ce:surname></sb:author><sb:author><ce:given-name>J.</ce:given-name><ce:surname>van Swieten</ce:surname></sb:author><sb:author><ce:given-name>P.</ce:given-name><ce:surname>Carmeliet</ce:surname></sb:author><sb:author><ce:given-name>L.</ce:given-name><ce:surname>Van Den Bosch</ce:surname></sb:author><sb:author><ce:given-name>W.</ce:given-name><ce:surname>Robberecht</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Progranulin functions as a neurotrophic factor to regulate neurite outgrowth and enhance neuronal survival</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Cell Biol.</sb:maintitle></sb:title><sb:volume-nr>181</sb:volume-nr></sb:series><sb:date>2008</sb:date></sb:issue><sb:pages><sb:first-page>37</sb:first-page><sb:last-page>41</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib35"><ce:label>Watts et al., 2004</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>G.D.</ce:given-name><ce:surname>Watts</ce:surname></sb:author><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Wymer</ce:surname></sb:author><sb:author><ce:given-name>M.J.</ce:given-name><ce:surname>Kovach</ce:surname></sb:author><sb:author><ce:given-name>S.G.</ce:given-name><ce:surname>Mehta</ce:surname></sb:author><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Mumm</ce:surname></sb:author><sb:author><ce:given-name>D.</ce:given-name><ce:surname>Darvish</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Pestronk</ce:surname></sb:author><sb:author><ce:given-name>M.P.</ce:given-name><ce:surname>Whyte</ce:surname></sb:author><sb:author><ce:given-name>V.E.</ce:given-name><ce:surname>Kimonis</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Nat. Genet.</sb:maintitle></sb:title><sb:volume-nr>36</sb:volume-nr></sb:series><sb:date>2004</sb:date></sb:issue><sb:pages><sb:first-page>377</sb:first-page><sb:last-page>381</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib36"><ce:label>Xu et al., 2011</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Xu</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Xilouri</ce:surname></sb:author><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Bruban</ce:surname></sb:author><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Shioi</ce:surname></sb:author><sb:author><ce:given-name>Z.</ce:given-name><ce:surname>Shao</ce:surname></sb:author><sb:author><ce:given-name>I.</ce:given-name><ce:surname>Papazoglou</ce:surname></sb:author><sb:author><ce:given-name>K.</ce:given-name><ce:surname>Vekrellis</ce:surname></sb:author><sb:author><ce:given-name>N.K.</ce:given-name><ce:surname>Robakis</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Extracellular progranulin protects cortical neurons from toxic insults by activating survival signaling</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Neurobiol. Aging</sb:maintitle></sb:title><sb:volume-nr>32</sb:volume-nr></sb:series><sb:date>2011</sb:date></sb:issue></sb:host><sb:comment>2326.e5-2326.e16</sb:comment></sb:reference></ce:bib-reference><ce:bib-reference id="bib37"><ce:label>Yamanaka, 2007</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Yamanaka</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Strategies and new developments in the generation of patient-specific pluripotent stem cells</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Cell Stem Cell</sb:maintitle></sb:title><sb:volume-nr>1</sb:volume-nr></sb:series><sb:date>2007</sb:date></sb:issue><sb:pages><sb:first-page>39</sb:first-page><sb:last-page>49</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib38"><ce:label>Yin et al., 2010</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>F.</ce:given-name><ce:surname>Yin</ce:surname></sb:author><sb:author><ce:given-name>R.</ce:given-name><ce:surname>Banerjee</ce:surname></sb:author><sb:author><ce:given-name>B.</ce:given-name><ce:surname>Thomas</ce:surname></sb:author><sb:author><ce:given-name>P.</ce:given-name><ce:surname>Zhou</ce:surname></sb:author><sb:author><ce:given-name>L.</ce:given-name><ce:surname>Qian</ce:surname></sb:author><sb:author><ce:given-name>T.</ce:given-name><ce:surname>Jia</ce:surname></sb:author><sb:author><ce:given-name>X.</ce:given-name><ce:surname>Ma</ce:surname></sb:author><sb:author><ce:given-name>Y.</ce:given-name><ce:surname>Ma</ce:surname></sb:author><sb:author><ce:given-name>C.</ce:given-name><ce:surname>Iadecola</ce:surname></sb:author><sb:author><ce:given-name>M.F.</ce:given-name><ce:surname>Beal</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>Exaggerated inflammation, impaired host defense, and neuropathology in progranulin-deficient mice</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Exp. Med.</sb:maintitle></sb:title><sb:volume-nr>207</sb:volume-nr></sb:series><sb:date>2010</sb:date></sb:issue><sb:pages><sb:first-page>117</sb:first-page><sb:last-page>128</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib39"><ce:label>Zanocco-Marani et al., 1999</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>T.</ce:given-name><ce:surname>Zanocco-Marani</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Bateman</ce:surname></sb:author><sb:author><ce:given-name>G.</ce:given-name><ce:surname>Romano</ce:surname></sb:author><sb:author><ce:given-name>B.</ce:given-name><ce:surname>Valentinis</ce:surname></sb:author><sb:author><ce:given-name>Z.H.</ce:given-name><ce:surname>He</ce:surname></sb:author><sb:author><ce:given-name>R.</ce:given-name><ce:surname>Baserga</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Biological activities and signaling pathways of the granulin/epithelin precursor</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Cancer Res.</sb:maintitle></sb:title><sb:volume-nr>59</sb:volume-nr></sb:series><sb:date>1999</sb:date></sb:issue><sb:pages><sb:first-page>5331</sb:first-page><sb:last-page>5340</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib40"><ce:label>Zhang et al., 2007</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>Y.J.</ce:given-name><ce:surname>Zhang</ce:surname></sb:author><sb:author><ce:given-name>Y.F.</ce:given-name><ce:surname>Xu</ce:surname></sb:author><sb:author><ce:given-name>C.A.</ce:given-name><ce:surname>Dickey</ce:surname></sb:author><sb:author><ce:given-name>E.</ce:given-name><ce:surname>Buratti</ce:surname></sb:author><sb:author><ce:given-name>F.</ce:given-name><ce:surname>Baralle</ce:surname></sb:author><sb:author><ce:given-name>R.</ce:given-name><ce:surname>Bailey</ce:surname></sb:author><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Pickering-Brown</ce:surname></sb:author><sb:author><ce:given-name>D.</ce:given-name><ce:surname>Dickson</ce:surname></sb:author><sb:author><ce:given-name>L.</ce:given-name><ce:surname>Petrucelli</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Progranulin mediates caspase-dependent cleavage of TAR DNA binding protein-43</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Neurosci.</sb:maintitle></sb:title><sb:volume-nr>27</sb:volume-nr></sb:series><sb:date>2007</sb:date></sb:issue><sb:pages><sb:first-page>10530</sb:first-page><sb:last-page>10534</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference></ce:bibliography-sec></ce:bibliography></tail></article></xocs:serial-item></xocs:doc>
